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I. INTRODUCTION 
Duchenne muscular dystrophy (DMD), a severe muscular wasting disease, is one of 
the most frequent lethal heritable disorders, affecting one in 3500 males (EMERY, 
1991). It is caused by a great variation of mutations in the DMD gene, positioned on 
the X-chromosome (MONACO et al., 1986; KOENIG et al., 1987), which lead to a 
loss of function of the protein dystrophin (HOFFMAN et al., 1987). Dystrophin is 
located at the membrane of muscle cells and, as a part of the dystrophin-glycoprotein 
complex (DGC), links actin filaments of the cytoskeleton to the extracellular matrix 
(ERVASTI, 2007). The loss leads to instability of the muscle membrane and 
eventually to muscle cell degeneration, although the precise pathological mechanisms 
are still unknown (DECONINCK & DAN, 2007). DMD is characterized by 
generalized progressive muscle weakness, which manifests at an average age of two to 
four years. The affected boys show an impaired motoric development, are wheelchair-
bound by the age of 12 years and die in their 2nd to 4th decade of life due to respiratory 
and cardiac failure (BLAKE et al., 2002). Up to this date no effective/curative 
treatment is available, however, several promising therapeutical approaches are 
currently under investigation (GOYENVALLE et al., 2011; PICHAVANT et al., 
2011), including treatments in early clinical trials (VAN DEUTEKOM et al., 2007; 
KINALI et al., 2009; CIRAK et al., 2011; GOEMANS et al., 2011). Animal models 
are needed to transfer promising new treatment strategies from basic research to 
clinical application, analyze and improve their efficiency, evaluate their (side-) effects 
on the organism and thereby develop a successful therapy (AIGNER et al., 2010). 
Already existing mammalian DMD animal models comprise various mouse models, 
dog models and a dystrophin deficient cat model (NAKAMURA & TAKEDA, 2011). 
Yet the existing animal models have different genotypical or phenotypical 
characteristics limiting their applications in biomedical research (WILLMANN et al., 
2009). The pig is a well-established animal model in biomedical research with several 
advantageous characteristics and diverse pig models have already been generated for 
different human diseases (LUNNEY, 2007; AIGNER et al., 2010). The establishment 
of nuclear transfer with genetically modified somatic cells (MCCREATH et al., 2000) 
enables the generation of tailored porcine animal models. For the introduction of a 
defined genetic modification bacterial artificial chromosomes (BACs) have 
successfully been used in mouse embryonic stem cells (TESTA et al., 2003; 
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VALENZUELA et al., 2003; YANG & SEED, 2003) and also in human embryonic 
stem cells (SONG et al., 2010). Efficient modification (ZHANG et al., 1998; 
COPELAND et al., 2001) and screening protocols (VALENZUELA et al., 2003; 
YANG & SEED, 2003) make them convenient tools for gene targeting experiments.  
The aim of this study was to generate a tailored porcine DMD animal model, by 
introducing a defined mutation into the DMD gene of primary porcine kidney cells 
using a modified bacterial artificial chromosome as targeting vector, followed by 
somatic cell nuclear transfer. 
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II. OVERVIEW OF LITERATURE 
1 X-linked muscular dystrophies 
The X-linked muscular dystrophies, Duchenne Muscular Dystrophy (DMD) and 
Becker Muscular Dystrophy (BMD), are characterized by progressive muscular 
weakness with differing severity. They are recessive monogenetic disorders of the 
dystrophin encoding DMD gene localized on the X-chromosome and are caused by a 
great variety of different mutations. X-linked muscular dystrophies affect mainly male 
persons, women are just rarely affected. DMD has an incidence of about 300 ×	 10-6, 
whereas the incidence of BMD is 45 ×	 10-6 (EMERY, 1991).  
Edward Meryon described DMD clinically and histologically for the first time in 1851 
at a meeting of the Royal Medical and Chirurgical Society (MERYON, 1851) and 
published his findings in the following year (MERYON, 1852). A few years later 
Guillaume Duchenne described the same disease and since then it has been called 
Duchenne muscular dystrophy (DUCHENNE, 1868). 
1.1 Clinical features 
Between the X-linked muscular dystrophies, DMD and BMD, the degree of clinical 
manifestation is continuous. The phenotypes vary greatly (MONACO et al., 1988). 
However, in the case of DMD and in severe cases of BMD the course of the disease is 
lethal, leading to a premature death of the affected persons in their twenties (EMERY, 
1993). 
The children seem normal at birth, but may already have increased serum creatine 
kinase (CK) levels (EMERY, 1977). First symptoms, caused by a progressive 
symmetrical weakness of the proximal lower limps, are apparent with about 2 – 5 
years. The boys start walking delayed, have difficulties in climbing stairs and gait 
problems, like waddling, unsteadiness and walking on tiptoes. Later on calf 
hypertrophy, a lordotic posture and a positive Gower’s sign (Figure  II.1) can be 
observed (GOWERS, 1879d, 1879c, 1879b, 1879a).  
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Figure  II.1 Gower’s sign 
Gower’s sign describes the typical way affected boys get up from a sitting to a standing 
position. They heave themselves up on their legs and straighten up by using their hands to 
walk up their legs; (GOWERS, 1879b). 
 
By the age of 12 years progression of muscle weakness and joint contractures 
eventually lead to the dependence on a wheelchair. Arms are affected later on in the 
course of the disease. The overall muscle weakness induces a kyphoscoliosis. A 
pseudo-hypertrophy of different muscles can be observed in some patients (EMERY, 
1993). Subsequent degeneration of respiratory and cardiac muscles most frequently 
causes the early death of the patients (BLAKE et al., 2002).  
In patients affected with BMD the course of the disease is normally far milder than 
that in patients with DMD (reviewed in BRADLEY et al., 1978). Yet the phenotype 
varies greatly from a severe Duchenne-like to almost asymptomatic (BEGGS et al., 
1991). Generally symptoms start delayed with around 12 years but it is possible that 
there are no apparent symptoms until much later. The progression of the disease is less 
rapid and also varies greatly. Furthermore, the life expectancy is much higher 
(EMERY, 1993). The criteria set by Jennekens facilitate the diagnosis by clinical 
manifestation (JENNEKENS et al., 1991). 
All patients affected by a mutation in the DMD gene, even some female carriers, have 
an elevated serum CK concentration (VERMA et al., 2010). This can be used as a 
screening method or for diagnostics. In some cases of DMD as well as BMD, a 
cognitive and verbal impairment can be observed (HINTON et al., 2000; MEHLER, 
2000) and there are also several cases in which solely the cardiac muscle is affected 
(FERLINI et al., 1999). 
The histological picture of muscle with a dystrophinopathy shows grouped 
II. Overview of literature   
 5 
degenerating or already necrotic fibers. In earlier stages there are signs of 
regeneration, such as centrally located nuclei, basophilic fibers and muscle fibers, 
which differ greatly in size (BELL & CONEN, 1968). Inflammatory cells like 
macrophages and CD4+ lymphocytes can be observed (MCDOUALL et al., 1990). 
Later on when the regenerating ability subsides there is an increase of fatty tissue and 
fibrous connective tissue (BLAKE et al., 2002). 
1.2 DMD gene 
DMD and BMD are caused by different mutations in the DMD gene. It has been 
shown that the diseases are allelic on this locus (KINGSTON et al., 1983a; 
KINGSTON et al., 1983b). The DMD gene has been localized to Xp21 on the 
X-chromosome (KUNKEL et al., 1985; RAY et al., 1985; MONACO et al., 1986; 
KOENIG et al., 1987). 
1.2.1 Genetic structure 
The DMD gene is composed of about 2.5 million base pairs and hence is the largest 
gene in the human genome. It comprises 79 exons and 7 different promoters with 
unique first exons (ROBERTS et al., 1993). Three independent promoters control the 
transcription of three different mRNAs sharing the same 78 exons, except for the first 
exon. The three promoters are named after the region of their predominant expression, 
brain, muscle and Purkinje promoter. The transcript of the brain promoter is mainly 
found in cortical neurons and the hippocampus. The product of muscle promoter is 
expressed in skeletal muscle cells, in cardiac muscle cells and in small amounts in 
glial cells of the brain and the Purkinje promoter is expressed in Purkinje cells and in 
skeletal muscle (BLAKE et al., 2002).  
Besides the three long isoforms (Dp427) transcribed from the above mentioned 
promoters, there are four shorter isoforms originating from four different promoters 
located upstream of their first exon in intronic region. The promoter of isoform Dp260 
(260 kDa) splices into exon 30. Dp260 is expressed in the retina together with the full-
length brain and muscle isoforms (PILLERS et al., 1993; D'SOUZA et al., 1995). The 
Dp140 isoform (140 kDa), having exon 45 as second exon, was found in brain, retina 
and kidney (LIDOV et al., 1995; DURBEEJ et al., 1997). Exon 56 is second exon for 
the isoform Dp116 (116 kDa), which is located in adult peripheral nerves (BYERS et 
al., 1993). The shortest isoform Dp71 (71 kDa) is transcribed from a promoter, which 
uses exon 63 as first exon. Dp71 can be found in several tissues except skeletal muscle 
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(LEDERFEIN et al., 1992; AHN & KUNKEL, 1993). Besides the seven isoforms 
originating in different promoters there are several other isoforms caused by 
alternative splicing (FEENER et al., 1989; AUSTIN et al., 1995) 
1.2.2 Mutations in the DMD gene 
There is a great diversity in location and size of the mutations in the DMD gene. This 
is caused by a high new mutation frequency of one third of all mutations, based on the 
Haldane rule (MOSER, 1984; HALDANE, 2004).  
The diversity of phenotypes can be ascribed to the mutational variance. Monaco stated 
1988 the reading frame rule and explaining thereby the correlation between mutation 
and phenotype (MONACO et al., 1988). Mutations leading to a reading frame shift 
and thus generally exposing the transcript to nonsense mediated mRNA decay (KERR 
et al., 2001; MAQUAT, 2004) cause the loss of the dystrophin protein and lead to a 
DMD phenotype, whereas mutations, which leave the reading frame intact, produce a 
shorter but at least partially functional protein and give rise to a BMD phenotype. The 
knowledge of the exon structure in combination with the reading-frame rule can be 
used to predict the phenotype of a given mutation (KOENIG et al., 1989). The reading 
frame rule applies to 90% of all DMD and BMD patients, but there are exceptions to 
this rule (AARTSMA-RUS et al., 2006). Some patients with an in-frame mutation still 
show a DMD phenotype when essential parts of the protein are missing or when the 
resulting protein is unstable. It is also possible that the mutation affects the splicing 
process of the RNA and produces an out-of-frame product (GUALANDI et al., 2003). 
Deletions of more than 35 exons in the rod domain cause DMD, whereas deletions 
with less exons results in a protein which appears to be partly functional (AARTSMA-
RUS et al., 2006). The complete loss of the actin-binding domain and parts of the 
central rod domain results also in a DMD phenotype (VAINZOF et al., 1993; 
ARIKAWA-HIRASAWA et al., 1995). A deleted cysteine-rich domain is always 
associated with DMD (BIES et al., 1992). Other patients show a Becker phenotype 
although the mutation changes the reading frame. The expression of a functional 
dystrophin in most of these cases is thought to be the result of exon skipping by 
alternative splicing. Deletions of exons do have different break points in the intronic 
sequence and might affect regulatory elements of the splicing machinery. It is also 
possible that factors regulating the splicing procedure have different expression levels, 
accounting for differences in patients with exactly the same mutation (reviewed in 
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MUNTONI et al., 2003 and AARTSMA-RUS et al., 2006).  
The frequency of intragenic deletion of exons in the DMD gene varies between 60% 
and 72%, depending on which database was used. The deletion can affect one or more 
exons. Duplication of one or more exons can be found in 7% of the patients. The 
remaining portion consists of smaller deletions, insertions, point mutations and 
intronic mutations (MUNTONI et al., 2003; AARTSMA-RUS et al., 2006; 
TUFFERY-GIRAUD et al., 2009).  
There are two mutational hotspots in the DMD gene (KOENIG et al., 1987; DEN 
DUNNEN et al., 1989). The first minor hotspot region extends from exon 2 to 20. The 
second and major region spans from exon 47 to 53, containing most deletions. 
Duplications are frequently found in the 5’ hotspot region (LIECHTI-GALLATI et al., 
1989; BEGGS et al., 1990). The reasons for this accumulation of large mutation in 
these regions are still unknown. However, it has been discovered that they correspond 
to major meiotic recombination hot spots (OUDET et al., 1992). Characterization of 
the deletion breakpoints showed that most of them can be found in just a few introns 
in the 3’ region whereas they are evenly distributed in the 5’ region (TUFFERY-
GIRAUD et al., 2009). Nonhomologous or illegimate recombination (IR) with 
nonhomologous end joining (NHEJ) is discussed to be involved in the generation of 
new mutations. But sequence analysis of the deletion breakpoints did not verify this 
theory (SIRONI et al., 2003).   
Point mutations seem to be evenly distributed. They can introduce premature stop 
codons, nonsense codons, cause a frame-shift or affect splice sites (reviewed in 
ROBERTS et al., 1994).  
1.3 Dystrophin protein 
The protein dystrophin is the product of the DMD gene (HOFFMAN et al., 1987). It 
has a molecular weight of 427 kDa and belongs to the β-spectrin/α-actinin protein 
family (KOENIG et al., 1988). It is located at the sarcolemma of the muscle cells and 
links γ-actin filaments of the cytoskeleton of muscle cells to the extracellular matrix 
(Figure  II.2). Being part of the dystrophin-glycoprotein complex (DGC), it is 
associated with the costameric proteins, which connect the Z disk of myofibrils over 
the membrane to laminin-2 in the extracellular matrix. Besides dystrophin the DGC 
includes α- and β-dystroglycans, α-dystrobrevin, syntrophin, sarcoglycans (α, β, γ, δ), 
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and sarcospan (ERVASTI, 2007).  
Dystrophin can be organized into four domains: the NH2-terminus, the central rod 
domain, the cysteine-rich domain and the COOH-terminal domain (reviewed in AHN 
& KUNKEL, 1993).  
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vesselassociated fetal stem cells known as ‘mesoangioblasts’
have been shown to provide widespread rescue of dystrophy in 
!-sarcoglycan-negative mice after femoral artery delivery; more-
over, lentiviral transduction of mesoangioblasts isolated from
dystrophic mice before injection gave similarly optimistic results
(Sampaolesi et al, 2003).
Aminoglycoside antibiotics
Between 5% and 15% of DMD cases are caused by premature
stop codons, and so the use of aminoglycoside antibiotics (for
example, gentamycin and negamycin), which promote trans-
lational readthrough of stop codons, has been investigated.
Despite hopeful results in mdx mice (6% dystrophin-positive
fibres, Arakawa et al, 2003; 10–20% of normal dystrophin levels,
Barton-Davis et al, 1999), no dystrophin expression has been
achieved in human studies of DMD and BMD patients and a repli-
cation of the mdx results have not been forthcoming (Dunant et al,
2003). Recent cell-culture experiments using eight different
patient mutations indicate that some sequences are better suppressed
by aminoglycosides than others (Howard et al, 2004).
Precise correction of the mutation
The precise correction of a dystrophin mutation can occur through
the use of short fragments or chimaeraplasts (double-stranded
RNA–DNA chimaeric oligonucleotides), which are designed to
contain the correct nucleotide. Unfortunately, intramuscular injec-
tions of chimaeraplasts have produced limited dystrophin protein in
the GRMD dog and mdx mouse, with dystrophin-positive cells
restricted to the area surrounding the injection site. Advances
include high conversion efficiencies in mdx muscle precursor cells
in vitro (2–15%, Bertoni et al, 2002) and induced exon skipping,
which led to a range of functional transcripts, protein expression
and localization (Bertoni et al, 2003). A 603-bp PCR product cor-
rected the mutant base in 15–20% of mdx myoblasts, but despite
the persistence of the corrected nucleotide for 3–4 weeks, the 
transfected cells lost viability and did not express any full-length
dystrophin transcript (Kapsa et al, 2001).
Antisense oligonucleotides
Antisense oligonucleotides can sterically inhibit gene expression
by hybridizing to target mRNA sequences at sites such as
exon–intron boundaries, translation inhibition codons and
sequences downstream of the initiation codon. The identification
of revertant fibres in dystrophic muscle that express the dystrophin
protein by exon skipping has guided the use of antisense oligo-
nucleotides for the genetic therapy of DMD (van Deutekom & van
Ommen, 2003). Researchers have tried to redirect dystrophin
splicing to exclude an exon that contains a premature stop codon
(for example, exon 23 in the mdx mouse model), in an effort to
restore the reading frame and to produce a slightly shorter, but
hopefully partially functional protein. Successful skipping has
been demonstrated in cultured mdx myotubes (Wilton et al, 1999),
the mdx mouse (Lu et al, 2003), and cultured muscle cells derived
from DMD patients (Aartsma-Rus et al, 2003). Hyaluronidase-
enhanced electrotransfer delivery of antisense olignucleotides has
been shown to result in dystrophin expression in 20–30% of fibres
in the tibialis anterior muscle of the mdx mouse after one injection
(Wells et al, 2003). Recent investigations into double-exon and
multi-exon skipping (skipping of numerous successive exons) have
enhanced the technique to treat a greater number of dystrophin
mutations with the same antisense oligonucleotides (Aartsma-Rus
et al, 2004). 
Proteasome inhibitors
Bonuccelli and coworkers (Bonucelli et al, 2003) explored the use
of proteasome inhibitors as a therapy for DMD on the premise that,
in the absence of dystrophin, members of the DAPC are degraded
through an unknown pathway that leads to their reduction in dys-
trophic muscle. Continuous systemic treatment of the proteasome
inhibitor MG-132—using a subcutaneously implanted osmotic
pump over eight days—resulted in decreased damage of the muscle
membrane and improved muscle integrity. The dystrophin protein
present at the plasma membrane after treatment lacked the C-termi-
nal domain due to the presence of the nonsense mutation in exon
23, and hence was a truncated form. These findings corroborate the
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Fig 2 | The dystrophin-associated protein complex in muscle linking the internal cytoskeleton to the extracellular matrix. NOS, nitric oxide synthase.
 
Figure  II.2 Dystrophin and its interactions with the other proteins of the 
dystrophin-g ycoprotein complex 
nNOS: nitric oxide synthase; fr m (NOWAK & DAVIES, 2004). 
 
The amino terminal domain has sequential and functional homologies to α-actinin and 
β-spectrin (KOENIG et al., 1988). The central rod omain is composed of 24 triple 
helical coiled-coil spectrin-like repeats, interspersed by four proline-rich hinge 
regions. The cysteine-rich domain consists of the two EF hand-like modules, the WW 
domain and the ZZ domain (KOENIG et al., 1988; BORK & SUDOL, 1994; 
PONTING et al., 1996). The WW domain is described as proline-rich protein binding 
domain, which can be found in other proteins involved in signaling and regulatory 
mechanisms (BORK & SUDOL, 1994). The two EF-hand motives show ho ologies 
to the calcium binding EF-hand motifs of α-actinin (KOENIG et al., 1988). The last 
part of the cysteine-rich region is the ZZ-domain. Like Zn2+ binding Zinc-Fingers this 
domain contains several cystein  residues (PONTING et al., 1996). The carboxy-
terminal domain of dystrophin includes coiled-coil motives, which are protein 
interaction domains (BLAKE et al., 1995). 
Interactions of dystrophin are depicted in Figure  II.2. The NH2-terminus and the 
central rod domain of dystrophin bind γ-actin (RYBAKOVA et al., 1996). The central 
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rod domain is thought to give flexibility to the protein (KOENIG & KUNKEL, 1990). 
β-dystroglycan is attached to dystrophin at the cysteine-rich domain and to some 
extent at the COOH-terminus. It is a transmembrane protein and binds to the 
extracellular α-dystroglycan, which is connected with laminin-2. The dystroglycans 
are also linked to sarcoglycans and sarcospan, thereby strengthening other molecule 
interaction in the DGC. The C-terminal domain is also the binding site of dystrobrevin 
and the syntrophins, which interact with several different signaling molecules, 
including the neuronal nitric oxide synthase (nNOS) (reviewed in ERVASTI, 2007).  
1.4 Pathomechanism 
There are several different approaches to explain the pathomechanism of muscular 
dystrophy (reviewed in BLAKE et al., 2002 and DECONINCK & DAN, 2007). 
However, the entire process is still unclear. One aspect might be that the loss of 
dystrophin leads to lesions in the cell membrane causing an increased fragility. This 
theory is supported by electron-microscopic findings, called delta lesions, and the 
detection of cytosolic molecules in the blood of DMD patients (MOKRI & ENGEL, 
1975). Additionally extracellular proteins could be identified in the cytoplasm of the 
mdx mouse, a DMD animal model (CLARKE et al., 1993; STRAUB et al., 1997). 
Another aspect of the pathomechanism is the elevated intracellular calcium 
concentration in DMD muscle cells (EMERY & BURT, 1980). An increased influx 
through mechanosensitive voltage-independent calcium channels might explain the 
higher level of calcium (VANDEBROUCK et al., 2002). Calcium ions activate 
proteases i.e. caplains, which hydrolyze proteins and thereby damage the cell. Since 
the role of the DGC in cell signaling pathways is not yet fully understood, there might 
be other processes involved in muscle damage, for example the possible impaired 
function of the enzyme nitric oxide synthase or changed gene expression patterns 
(RANDO, 2001; DECONINCK & DAN, 2007).  
1.5 Therapeutical approaches for DMD  
Up to this date there is no effective therapy for DMD. Treatments for DMD patients at 
the moment are aimed at the amelioration of symptoms. Glucocorticoids, such as 
prednisone and deflazocort, are administered as they have positive effects on muscles 
(MANZUR et al., 2008). Furthermore, physical medicine and rehabilitation are 
important parts of the patient’s management (VERMA et al., 2010). However, there 
are several different new therapeutical approaches studied right now, which comprise 
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various pharmacological strategies, gene replacement and exon skipping (reviewed in 
GOYENVALLE et al., 2011 and PICHAVANT et al., 2011).  
Pharmaceutical approaches include the upregulation of the expression of the protein 
utrophin and read-through strategies for nonsense mutations. Utrophin is an 
orthologous protein of dystrophin, normally expressed during embryogenesis and later 
on at neuromuscular and myotendinous junctions (KHURANA et al., 1991; TINSLEY 
et al., 1992). There are great structural and functional similarities relevant for 
therapeutical application between utrophin and dystrophin (reviewed in PERKINS & 
DAVIES, 2002), giving rise to several different approaches to regulate transcription of 
utrophin (GOYENVALLE et al., 2011). Read-through strategies are just relevant for 
DMD patients with a mutation causing a stop codon. Some drugs, such as Gentamicin 
and Ataluren, introduce an amino acid at a premature stop codon, causing the 
translation to carry on (PICHAVANT et al., 2011).  
Rather than repairing the defect in the DMD gene, the aim of gene replacement is to 
introduce another functional copy of the DMD gene in muscle. Viral vectors, such as 
lentiviral, adenoviral and adeno-associated viral vectors (AAV), are currently used as 
a method of gene delivery. Physical approaches such as hydrodynamic pressure or 
electroporation are also available. Lentiviral vectors transduce proliferating and 
terminally differentiated muscle cells (LI et al., 2005). However, their transduction 
rate in vivo is low and they may cause insertional mutagenesis (MACKENZIE et al., 
2005; BEARD et al., 2007). Initial experiments with adenoviral vectors were 
promising, but in non-human primates and in humans they initiated major adverse 
immunological effects (RAPER et al., 2003; BRUNETTI-PIERRI et al., 2004). 
Mainly recombinant AAV (rAAV) vectors are used in clinical trials. Several different 
serotypes are described, but just rAAV1, 6, 7, 8 and 9 are interesting for muscular 
application (SCHULTZ & CHAMBERLAIN, 2008). The limited carrying capacity of 
viral vectors requires modifications of the DMD gene to reduce its size. On the basis 
of BMD patients with great deletions in the DMD gene mini- and micro-dystrophin 
cDNA genes were constructed with deletions in the rod domain and the C-terminal 
(HARPER et al., 2002).   
Mutations causing DMD generally disrupt the reading frame, whereas mutations, 
which leave the reading frame intact, give rise to a BMD phenotype. Antisense-
induced exon-skipping strategies try to convert an out of frame deletion into an in 
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frame deletion by skipping one or more exons and induce a BMD phenotype, with a 
shortened but functional dystrophin (AARTSMA-RUS et al., 2009). Table II.1 
indicates the mutations listed in the Leiden DMD database, which can be treated with 
skipping of certain exons and the percentage of the affected patients within the 
database (VAN DEUTEKOM & VAN OMMEN, 2003). 
Table II.1  Overview of theoretic therapeutic exon skipping for certain 
DMD mutations 
NATURE REVIEWS | GENETICS VOLUME 4 | OCTOBER 2003 | 779
R E V I EW S
targeting both exon 51 splice sites was especially effective
in inducing skipping in more than 60% of cells, which
introduced the synthesis of a new shorter dystrophin.
Perspectives. Although exon skipping is a mutation-
specific therapy, an important intrinsic advantage
compared with conventional gene therapy is that it
simultaneously corrects all dystrophin isoforms. It also
maintains the original tissue-specific gene regulation.
Moreover, AONs are small, sequence specific and syn-
thetic, and so are relatively safe therapeutic agents.
Although the results so far seem to support short-term
therapeutic potential, several parameters need to be
optimized for clinical application.
One such parameter is the choice of target sequence.
As an exon will only be included in the mRNA when the
spliceosomal complex recognizes both splice sites, these
seem obvious targets for AONs. However, the mdx stud-
ies indicate that the design of AONs that target splice
sites might be crucial. By contrast, a strategy that targets
The broad therapeutic potential of AONs was
shown in cultured muscle cells from DMD patients
that were affected by several different deletions66 (for
example, exons 45–54) (FIG. 2). In all cases, the tar-
geted exon was specifically skipped and at relatively
high levels of up to ~90% (such as in FIG. 3a), which
induced the synthesis of significant levels of dys-
trophin in more than 75% of treated cells (FIG. 3b,c).
These dystrophins located appropriately to the sar-
colemma and restored the dystrophin–glycoprotein
complex, which was a strong indication of functional
restoration.
In a parallel study that targeted the splice sites of
exon 51, a more permanent bypass of the deletion 
of exons 48–50 was achieved67. Here, the antisense
sequences were cloned into small nuclear RNAs
(snRNAs), which were delivered to cultured muscle
cells by a recombinant retrovirus. Small integrated ‘fac-
tories’ were therefore introduced, which stably and effi-
ciently produced the antisense sequences. The construct
Table 3 | Overview of therapeutic exon skipping for a series of DMD-causing deletions
Skippable Therapeutic for DMD deletions (exons) Percentage of deletions
exon in LDMD database
2 3–7, 3–19, 3–21 2.9
8 3–7, 4–7, 5–7, 6–7 4.5
17 12–16, 18–33, 18–41, 18–44 1.8
43 44, 44–47, 44–49, 44–51 3.7
44 14–43, 19–43, 30–43, 35–43, 36–43, 40–43, 42–43, 45, 45–54 7.8
45 12–44, 18–44, 44, 46–47, 46–48, 46–49, 46–51, 46–53, 46–55 11.2
46 21–45, 45, 47–54, 47–56 5.6
50 51, 51–53, 51–55 5.2
51 45–50, 47–50, 48–50, 49–50, 50, 52, 52–63 17.5
52 51, 53, 53–55 4.0
53 10–52, 45–52, 46–52, 47–52, 48–52, 49–52, 50–52, 52 7.5
55 45–54, 48–54 1.8
Total 12 AONs 73.5
This series of Duchenne muscular dystrophy (DMD)-causing deletions were reported in the Leiden DMD (LDMD) database. Antisense
oligonucleotide (AON)-induced skipping of just 1 of the 12 skippable exons listed would (theoretically) restore the reading frame in a series
of DMD patients that were affected by different deletions.
43 44 55
43 55
a  b c
NT 2d 4d 7d HC
Figure 3 | Therapeutic exon skipping in cultured myotubes from a DMD-patient (DL363.2) with a deletion of exons 45–54.
After transfection with an exon-internal antisense oligoribonucleotide (AON) in exon 44 (44AON1), exon 44 skipping was induced
such that most transcripts were in-frame. a | RT-PCR of the region spanning exons 43–55 shows that in the untreated myotubes
almost all of the transcripts are out-of-frame and contain exon 44 (lane 2), whereas in AON-treated myotubes most transcripts
(~90%) are in-frame and are missing exon 44 (lane 3). b,c | Exon skipping also led to substantial dystrophin synthesis in situ, which
was detected by the immunohistochemical analysis of treated myotubes (b) and by Western blot analysis of protein samples from
treated myotubes (c) using the Dys2 antibody (raised against the distal exons 77–79). The dystrophin was located at the membrane
at two days (2d) and accumulated up to seven days (7d) post-transfection. No dystrophin was observed in untreated samples (NT).
As expected from the deletion, the dystrophin that was produced was shorter than the full-length dystrophin from a (1:10 diluted)
human control sample (HC). Parts b and c reproduced with permission from REF. 66 © (2003) Oxford Univ. Press.
 
from: (VAN DEUTEKOM & VAN OMMEN, 2003) 
 
Synthetic single-stranded DNA or RNA molecules with a length of about 25 bp bind 
to specific splice motifs of the pre-mRNA and thereby causing the desired exon to be 
left out in the mature mRNA. 2’-O ethyl-phosphorothioates (2OMe) and 
p osphor diamidate morpholino oligomers (PMO) differ from each other in chemical 
modifications of the oligo ucleotides to enha ce th ir pharmaceutical properties 
(reviewed in NAKAMURA & TAKEDA, 2009). Improvem nt of the cellular uptake 
 PMOs is expe ted by fusing different molecules to PMOs, for example an arginine-
rich peptide (pPMO). However, pPMOs show a t xic effect in kidneys (AMANTANA 
et al., 2007; MOULTON & MOULTON, 2010). Clinical trials on the basis of 
skipping exon 51 have been conducted and had promising results (VAN DEUTEKOM 
et al., 2007; KINALI et al., 2009; CIRAK et al., 2011; GOEMANS et al., 2011). 
Improvements in body-wide distribution with effective levels and an overall 
enhancement of the exon skipping efficiency is still essential (WOOD, 2010). 
Immunological reactions against the vectors or even against the newly build 
dystrophin are aspects, which have to be considered in further developments 
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(MENDELL et al., 2010; MOORE & FLOTTE, 2010).  
2 DMD animal models 
Available options for treatment of DMD are still insufficient. Animal models are 
needed to transfer promising new treatment strategies from basic research to clinical 
application and analyze their potential and efficiency as well as the adverse effects 
(AIGNER et al., 2010). There are certain requirements an animal model should 
comply with. The genetic basis for the muscular dystrophy in animals should resemble 
the human situation. Furthermore, should the model’s phenotype approximate the 
human phenotype and variation in phenotype between individual animals should be 
minor, also over generations, to ensure comparability of experiments. The animal 
model should be well characterized, easy and inexpensive to maintain and easy to 
handle (WILLMANN et al., 2009).  
2.1 Murine DMD models 
Various different DMD mouse models have been established. Several of the mouse 
models display mutations in the Dmd gene, however, there are also mouse models, 
which have additionally other genes affected. The mdx mouse has a spontaneous 
mutation occurring in the Dmd gene, whereas the other mouse models have mutations 
introduced by targeting or derived from N-ethyl-nitrosourea (ENU) chemical 
mutagenesis treatment. 
The mdx mouse was the first discovered DMD mouse model. It has a point mutation 
in exon 23 of the Dmd gene, which occurred naturally in the C57BL/10 strain, leading 
to a premature stop codon (BULFIELD et al., 1984). The observed pathology in 
affected mice is less severe than that in human DMD patients and they have just a 
slightly reduced lifespan. From 2 to 8 weeks of age their muscle pathology is most 
pronounced, with elevated serum CK levels and showing marked degeneration and 
regeneration, with necrotic muscle fibers and newly generated fibers with centrally 
located nuclei and differing sizes. From 8 weeks on the pathological changes decrease 
to a lower level (MCGEACHIE et al., 1993) and the muscle weakness just becomes 
obvious in old age (LEFAUCHEUR et al., 1995). Muscle fibrosis in mdx mice is less 
striking than that in DMD patients, except for the diaphragm (MULLER et al., 2001). 
The heart muscle is also affected, partially resembling the human DMD heart 
phenotype (QUINLAN et al., 2004). Skeletal muscle pathology can be worsened by 
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increased exercise (WILLMANN et al., 2009). There are several different approaches 
to explain the mild phenotype of the mdx mice. First of all, mice seem to have a higher 
regenerative capacity compared to human. They also might compensate the loss of 
dystrophin with the homologous protein utrophin (DURBEEJ & CAMPBELL, 2002).  
Four additional DMD mouse models (mdx2Cv, mdx3Cv, mdx4Cv and mdx5Cv) were 
created by treating mice with the chemical mutagen ENU (CHAPMAN et al., 1989). 
mdx2Cv and mdx3Cv mice both have a point mutation in the splice acceptor sequence in 
intron 42 and in intron 65 respectively. A point mutation in exon 53 in mdx4Cv leads to 
a premature stop codon and mdx5Cv mice display a new splice donor caused by a point 
mutation in exon 10 (IM et al., 1996; COX et al., 1993). Although they show varying 
mutations in the Dmd gene, affecting the expression of different dystrophin isoforms, 
their phenotype mainly resembles that of the mdx mouse with slight differences, 
(reviewed in WILLMANN et al., 2009).  
A complete deletion of the Dmd gene has been achieved using the Cre-loxP 
recombination system. Although the resulting DMD-null mice do not express any 
dystrophin isoforms, their phenotype does not differ considerably from the mdx 
phenotype. However, changes in behavior were reported in DMD-null mice (KUDOH 
et al., 2005).  
In order to create a DMD mouse model, which also affects shorter dystrophin 
isoforms, exon 52 knockout mice were generated by targeted mutagenesis, imitating a 
human mutation leading to a DMD phenotype. In mdx52 mice expression of 
dystrophin isoforms Dp140, Dp260 and Dp427 is disrupted, whereas the expression of 
isoforms Dp71 and Dp116 is not affected. The mdx52 mice do not show any obvious 
signs of muscular weakness up to 1 year of age. Yet the limb muscles of affected 
animals display a hypertrophy similar to that in DMD patients. Degeneration and 
regeneration of muscle fibers can be observed, but there is no apparent fibrosis or fat 
infiltration. The diaphragm is markedly affected (ARAKI et al., 1997). The loss of 
Dp260, which is located in the retina, may cause an abnormal electroretinogram 
(KAMEYA et al., 1997). But the loss of Dp140, located in the brain, does not give 
rise to pathological changes in the brain and the behavior seemed normal. The 
pathology of the mdx52 is similar to that of the mdx mice, except for the hypertrophy 
of the limb muscles and the abnormal electroretinogram (ARAKI et al., 1997).  
Besides the mouse models, which affect just the Dmd gene, there are several other 
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mouse models displaying an additional mutation in another gene, like the utrophin, 
MyoD, α-dystrobrevin, α7β1intergrin and parvalbumin gene. These mouse models 
were established to aggravate the phenotype and to obtain information about 
functional importance of the deleted genes (WILLMANN et al., 2009).  
2.2 Canine DMD models 
X-linked muscular dystrophy caused by spontaneous mutations in the DMD gene has 
been discovered in divers dog breeds, amongst others the Golden Retriever (COOPER 
et al., 1988), the German Short-Haired Pointer (SCHATZBERG et al., 1999) and the 
Cavalier King Charles Spaniel (WALMSLEY et al., 2010). The mutation of the 
Golden Retriever Muscular Dystrophy (GRMD) has been characterized (SHARP et 
al., 1992) and introduced into Beagles, giving rise to the Beagle-based Canine 
X-linked Muscular Dystrophy in Japan (CXMDJ) (SHIMATSU et al., 2003).  
The two most widely used canine models are based on a naturally occurring mutation 
found in Golden Retriever. This point mutation is localized in the canine DMD gene at 
the acceptor splice site in intron 6, resulting in the skipping of exon 7 and in 
consequence in a premature stop in exon 8 (SHARP et al., 1992). The characteristics 
of GRMD are similar to those of DMD, however, the phenotypes are very variable 
(AMBROSIO et al., 2009). Generally the muscle weakness is progressive and the 
muscles show extensive degeneration and necrosis from birth onwards. Impairment of 
motoric abilities can be observed. Later on muscle fibrosis and joint contractures give 
rise to skeletal deformations and hypertrophy of tongue, pharynx and oesophagus 
muscles, which cause problems like regurgitation and dysphagia. GRMD dogs also 
develop a cardiomyopathy and the serum CK concentration is always increased 
(COOPER et al., 1988; VALENTINE et al., 1988).  
The beagle DMD model (CXMDJ) and the GRMD dogs resemble each other in their 
phenotype, although the manifestation of the symptoms is milder in CXMDJ and the 
dogs are easier to handle because of their smaller size (WILLMANN et al., 2009).  
Recently Cavalier King Charles Spaniels with muscular dystrophy were discovered 
(CKCS-MD). A missense mutation in the 5’ donor splice site of exon 50 results in the 
deletion of this exon. The phenotype of the 3 dystrophic dogs, described in this study, 
seems to resemble that of the GRMD and CXMDJ dog models (WALMSLEY et al., 
2010).  
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2.3 Feline DMD models 
Dystrophinopathy in cats has been described as hypertrophic feline muscular 
dystrophy (HFMD) (VOS et al., 1986; CARPENTER et al., 1989; GASCHEN et al., 
1992). The deletion of the muscle and Purkinje promoters results in the loss of 
dystrophin in skeletal and heart muscle (WINAND et al., 1994). The main 
characteristic of the disease is the marked muscle hypertrophy of the skeletal muscles 
and especially the tongue muscles. This leads to a stiff, bunny-hopping gait, decreased 
exercise tolerance, increased salivation and regurgitation (SHELTON & ENGVALL, 
2005). Histology shows degenerating and regenerating fibers and calcification spots, 
but it does not show any fibrosis. The serum CK concentration is increased and 
HFMD cats additionally display a dilated cardiomyopathy (GASCHEN et al., 1999). 
Affected cats eventually die due to a compression of the esophagus by the 
hypertrophic diaphragm or because of renal failure, caused by a decreased water 
intake due to an enlargement of the tongue (GASCHEN et al., 1992).  
2.4 Other DMD models 
Dystrophin orthologous have been described in several different non-mammalian 
animals, like zebrafish, C. elegans, Drosophila and the sea urchin. Zebrafish have also 
orthologs of most DGC proteins with similar localization at the membrane. 
Dystrophin deficiency in fish causes a bent morphology and reduced activity 
(GUYON et al., 2003). C. elegans express a dystrophin homologue dys-1. Mutations 
in this gene lead to hyperactivity, hypercontraction and increased sensitivity to 
acetylcholine and its inhibitor (BESSOU et al., 1998). 
2.5 DMD models for therapeutical approaches 
A DMD animal model for therapeutical approaches has to comply with several 
different requirements as mentioned above. Using mouse models in DMD research 
has various reasons. They are very well characterized, easy and inexpensive to 
maintain, easy to handle and have a consistent genetic background and phenotype 
(GROUNDS et al., 2008). A major drawback of murine DMD models is their 
relatively mild phenotype compared to human and past failures of therapies, which 
worked in mice but did not work in humans (COLLINS & MORGAN, 2003). 
Additionally does the DMD-null mouse model not display a mutation found in human 
and a complete knockout of the Dmd gene reduces the number of treatment 
approaches, which can be tested with this model. Double knockout mice are not 
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suitable for therapy testing due to the lack of concordance between their double 
mutations and the human mutations, although their phenotype may have a higher 
resemblance to the human phenotype. The GRMD, the CXMDJ and the CKCS-MD 
dog models seem to be appropriate DMD models, because they have a very similar 
phenotype to human DMD patients and a similar size. However, the severity varies 
greatly between individuals, what makes comparison of experiments difficult. High 
expenses for maintaining colonies are another disadvantage of using dogs as models 
for DMD in pre-clinical testing (WILLMANN et al., 2009). Dystrophic cats are not 
often used as DMD models, because their phenotype varies greatly from human DMD 
patients and the expenses to maintain colonies are high. Large numbers of the non-
mammalian animal models, the potential for genetic manipulation, high 
reproducibility of experiments and easy breeding and maintenance make them suitable 
for the usage in high-throughput initial studies, although their musculature and their 
phenotype do not resemble the phenotype of human DMD patients (COLLINS & 
MORGAN, 2003). 
Several different studies for therapeutical applications have been conducted with the 
existing models (NAKAMURA & TAKEDA, 2011). One has to bear the limitations 
of each animal model in mind when evaluating the results. The mdx mouse has been 
used for exon skipping experiments with 2OM antisense oligonucleotides (LU et al., 
2003), PMO (FLETCHER et al., 2006; WELLS, 2006), pPMO 
(JEARAWIRIYAPAISARN et al., 2008) and also with recombinant AAVs as vectors 
for exon-skipping experiments (GOYENVALLE et al., 2004) and for gene 
replacement experiments (GREGOREVIC et al., 2004; WANG et al., 2005; BISH et 
al., 2008). Mdx52 mice can also be used for exon-skipping therapy trials. There are 
several human DMD patients, which would benefit from this approach. Skipping exon 
51 in these models is supposed to restore the reading frame. Recently PMO were used 
to skip exon 51 successfully (AOKI et al., 2010). Gene therapy experiments with 
adenoviral vectors and AAV vectors with mini-dystrophins (HOWELL et al., 1997; 
HOWELL et al., 1998; KORNEGAY et al., 2010) and chimeric RNA/DNA 
oligonucleotide for exon-skipping were tested in the GRMD dog (BARTLETT et al., 
2000). 2OMe, PMO or pPMO have been compared in cultured GRMD muscle cells 
(MCCLOREY et al., 2006). In CKCS-MD muscle cell cultures skipping of exon 51 
restored the reading frame and protein expression (WALMSLEY et al., 2010). In 
CXMDJ dog model experiments with multiexon skipping via PMOs and experiments 
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to evaluate efficiency of rAAVs have been conducted (YUASA et al., 2007; 
OHSHIMA et al., 2009; YOKOTA et al., 2009).  
3 Genetic engineering of large animal models 
Genetic diseases are caused by mutations, which lead to an alteration of function. In 
the case of DMD mutations of the DMD gene lead to the loss of the dystrophin 
function. Up to this date there is no curative/effective treatment available for DMD. 
Animal models with a corresponding functional deficiency are needed for further 
research and particular for developing a successful therapy. Yet existing animal 
models are of limited relevance, because they do not meet the requirements of a 
satisfactory DMD model. Therefore, a more suitable model is required. In order to 
create an animal model with a corresponding loss of function a site directed 
mutagenesis of the desired gene, in this case of the DMD locus, is necessary. This can 
either be achieved by homologous recombination, by designer nucleases like zinc 
finger nucleases (ZFN) or by combination of both. With the exception of mouse, and 
more recently rats, no germ line competent embryonic stem cells (ESCs) are available. 
Thus alternative technologies are inevitable for the generation of site-directed 
mutations in other species. To date somatic cell nuclear transfer (SCNT) of genetically 
modified cells is the preferred method establishing a model with defined targeted 
mutations (reviewed in AIGNER et al., 2010).  
3.1 Large animal models/pig models 
Several similarities between humans and pigs make the pig a suitable model for 
humans in various fields of medical research. They have got a similar size, anatomy, 
physiology, metabolism and pathology (reviewed in LUNNEY, 2007). Reproductive 
characteristics like an early sexual maturity, a short generation interval, large litter 
size, no seasonal break in breeding and also standardized housing conditions 
(REHBINDER et al., 1998) are advantageous (reviewed in AIGNER et al., 2010).   
The pig genome is almost completely sequenced. Data are permanently updated on the 
Ensembl website (http://www.ensembl.org/Sus_scofa/Info/Index). Bioinformatics 
analyses on the pig genome are only rudimentary available. But comparison of 
representative exonic, intronic, 3’UTR, 5’UTR, intergenic regions and miRNAs of 
human, pig and mouse revealed a greater phylogenetic similarity between human and 
pig than between human and mouse (WERNERSSON et al., 2005). The cDNA 
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analysis of human, mouse and pig proteins supports this thesis (JORGENSEN et al., 
2005). 
Pigs, even without genomic alterations, have proven to be adequate models in various 
diseases (LUNNEY, 2007). Genetically modified porcine models were established for 
neurodegenerative diseases, cardiovascular diseases (reviewed by AIGNER et al., 
2010), cystic fibrosis (ROGERS et al., 2008) or diabetes mellitus (RENNER et al., 
2010). Pigs do also play a major role in xenotransplantation (KLYMIUK et al., 2010).   
3.2 Nuclear transfer 
SCNT of genetically modified primary cells overcomes the lack of porcine ESCs. In 
SCNT nuclei of donor cells obtained from various tissues are transferred in enucleated 
oocytes or zygotes (reviewed in WOLF et al., 1998). This technology has various 
favorable characteristics. Donor cells can be pre-selected and screened regarding 
gender or transgene integration qualities, the resulting organisms are genetically 
identical and they are not a mosaic (AIGNER et al., 2010). Even so comparison of 
SCNT efficiency is difficult due to differences in experimental protocols, embryo 
selection and data presentation, it is generally below 5% (CAMPBELL et al., 2005). 
The low efficiency is ascribed to incorrect epigenetic reprogramming (SHI et al., 
2003), causing abnormalities of placenta, embryos, fetuses and offspring (ZHAO et 
al., 2010). Abnormalities in pigs include contracted tendons and enlarged tongues 
(PRATHER et al., 2004). 
For the first time successful application of somatic cells in nuclear transfer was 
reported in sheep (WILMUT et al., 1997). Since then various transgenic animal 
models have been established in various animal species, such as sheep, goats and 
cattle (MCCREATH et al., 2000; DENNING et al., 2001; KUROIWA et al., 2004; 
SENDAI et al., 2006; YU et al., 2006; RICHT et al., 2007; KUROIWA et al., 2009; 
ZHU et al., 2009). It was later on also established in pigs, using fetal fibroblasts, 
cultured adult granulosa cells and fetal cells (BETTHAUSER et al., 2000; ONISHI et 
al., 2000; POLEJAEVA et al., 2000). Targeted genes of the porcine genome comprise 
the alpha-1,3-galactosyltrasnferase (GGTA1) (LAI et al., 2002), cystic fibrosis 
transmembrane conductance regulator (CFTR) (ROGERS et al., 2008), the kappa light 
chain constant region (RAMSOONDAR et al., 2011) and the heavy chain joining 
region (MENDICINO et al., 2011).  
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3.3 Introduction of DNA into primary cells 
For the site-directed genetic modification of the primary cells used as donor cells in 
SCNT DNA or RNA has to be introduced into the cells. This can be achieved either 
by viral or non-viral methods. Non-viral methods can be divided in to chemical or 
physical methods.  
Viral gene transfer presents one possibility to insert a transgene into the genome of 
cells. Known viral systems used for gene transfer are prototypic retroviruses, 
lentiviruses and AAVs. However, only AAVs, single stranded parvoviruses with 
several serotypes and differing tissue tropisms, have been described to perform site-
directed mutagenesis (RUSSELL & HIRATA, 1998) and one tailored pig model was 
established (ROGERS et al., 2008). Other viral gene transfer systems, like lentiviruses 
(PFEIFER, 2004), can be used successfully for producing transgenic animals 
(HOFMANN et al., 2003). They transport the transgenes directly into the nucleus 
enabling transgenesis of dividing and non-dividing cells, but the integration of the 
transgenes occurs randomly, which may cause unwanted side effects. The genetic 
material of retroviruses undergoes extensive silencing when inserted into the host 
genome impairing the expression (FOLLENZI et al., 2000; HOFMANN et al., 2006). 
It has to be taken under consideration that the packing capability of viral vectors is 
limited to < 10 kb at most (ROBL et al., 2007), AAV vectors even just being able to 
carry 4.5 kb of foreign material (HENDRIE & RUSSELL, 2005).  
Chemical introduction of nucleic acids is achieved by lipofection, calcium phosphate 
precipitation, cationic polymers or molecular conjugates. Physical methods include 
biolistic bombardment technique, microinjection and electroporation (COLOSIMO et 
al., 2000). The nucleofection technology is a further development of electroporation 
and presents a combination of chemical and physical methods. Lipofection, 
electroporation and nucleofection are the most commonly used non-viral transfection 
methods for primary cells today. Lipofection is based on the delivery of DNA or RNA 
via encapsulation in cationic liposomes (FELGNER et al., 1987). These artificial 
particles either fuse with the cell membrane or enter the cell via endocytosis. 
Lipofection can reach a relatively high efficiency, however, reaction conditions, such 
as DNA and liposome ratio, have to be optimized for each experiment. Several 
different formulas for lipofection are available (RECILLAS-TARGA, 2006). 
Electroporation delivers the genetic material into the cell by electric pulses, which 
lead to the permeabilisation of the cell membrane for DNA molecules (NEUMANN et 
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al., 1982). Due to an increased cell death after electroporation, the parameters, like 
pulse length and strength, have to be optimized for differing cell types and also for 
different DNA molecules. Nucleofection combines electroporation with cell type 
specific solutions in order to transport the genetic material directly into the nucleus in 
contrast to other methods, which transfer DNA or RNA just into the cytoplasm 
(HAMM et al., 2002). For each cell type specific nucleofection solutions and 
electroporation programs have been established in order to increase efficiency and 
minimize cell death (MAURISSE et al., 2010). Targeting efficiency, cell toxicity and 
number of random integration events differ greatly between all these methods, also 
depending on which cell type and transfection conditions are used. Several studies 
have been conducted to determine the most efficient method. Earlier studies 
comparing lipofection and other chemical methods, with electroporation showed that 
electroporation seems to be the most efficient method (YANEZ & PORTER, 1999; 
VASQUEZ et al., 2001). More recent studies, which compare nucleofection with 
lipofection and electroporation for several different cell types generally revealed a 
higher targeting efficiency of nucleofection. Though cytotoxicity also seems to be 
higher with nucleofection compared to lipofection (JACOBSEN et al., 2006; CAO et 
al., 2010; MAURISSE et al., 2010; MO et al., 2010). However, one study comparing 
lipofection with nucleofection states that nucleofection is less efficient, but also less 
cytotoxic (SKRZYSZOWSKA et al., 2008). 
3.4 Site directed mutagenesis of primary cells 
Today site-specific genome modification of primary cells can either be achieved by 
homologous recombination (HR), by designer nucleases like ZFN or by combination 
of both. The first gene targeting was accomplished in erythroleukemia cells at the 
human the β–globin locus (SMITHIES et al., 1985). Gene targeting via homologous 
recombination makes use of the cell’s own repair mechanisms for double strand 
breaks (DSB). DSB occur naturally in all cell types and are either repaired by 
nonhomologous end joining (NHEJ) or by HR (HABER, 2000). In HR a homologous 
DNA molecule is used to repair the DNA strand carrying the DSB. The mechanism of 
homologous recombination may be accomplished by three different pathways, all of 
them beginning with the resection of the 5’end of the DSB. Processes of HR and 
NHEJ are reviewed by HABER, 2000 and PARDO et al., 2009. When introducing a 
DNA fragment, which is homologous to a specific sequence, it is assumed that the 
DNA fragment locates to and recombines with its homologous region in the cell’s 
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genome mediated by the available DNA repair enzymes (SORRELL & KOLB, 2005). 
However, the foreign molecules are also inserted randomly, which may be caused by 
NHEJ (VASQUEZ et al., 2001). Generally HR is a rare event and occurs in about 1 
per 105 or 106 treated cells, 3-4 × 104 times less frequent than NHEJ in mouse ESCs 
and even less frequent in primary somatic cells (DOETSCHMAN et al., 1987; 
SEDIVY & SHARP, 1989; HASTY et al., 1991; SEDIVY & DUTRIAUX, 1999). 
Also did comparison of targeting efficiency of an active and a non-expressed gene 
show that an expressed gene can be more easily targeted (KUROIWA et al., 2004). 
3.4.1 Vectors for gene targeting  
Gene targeting can be achieved either by introduction of any mutation at a defined site 
or by the integration of a defined mutation. The first one is often done when a DSB 
occurs, which can be artificially caused by ZFN. The DSB is repaired by NHEJ and 
may result in mutations leading to a loss of function of the targeted gene (PORTEUS 
& CARROLL, 2005). Defined mutations require vectors carrying the designed 
modification as well as sequences upstream and downstream of the modification 
cassette, which are homologous to the target locus and thus facilitate HR between the 
genome and the vector. The length of homology between the DNA sequence of vector 
and genome target locus is said to play a major role in efficiency: a longer homology 
leads to an increase in frequency (DENG & CAPECCHI, 1992; SCHEERER & 
ADAIR, 1994). Large vectors such as yeast artificial chromosomes (YACs), P1 
artificial chromosomes (PACs) or bacterial artificial chromosomes (BACs) thus 
increase the rate of HR. It may not be necessary that the sequence of the DNA 
molecule is isogenic for targeting in all cell types (SEDIVY et al., 1999), although it 
was shown to be beneficial for targeting frequency in mouse ESCs (TE RIELE et al., 
1992).  
AAVs provide, in addition to the efficient transfer of exogenous DNA into the nucleus 
of the target cell an additional benefit: they have a relatively high targeting efficiency. 
A successful targeting of the CFTR gene has been achieved in the pig using AAVs as 
targeting vector with targeting efficiencies from 0.07 to 10.93%. Although these 
numbers include targeted cell clones, which were not examined for randomly 
integrated constructs (ROGERS et al., 2008). The exact mechanism of integration is 
still discussed (HENDRIE & RUSSELL, 2005; SCHULTZ & CHAMBERLAIN, 
2008), but it is known that an increase in length of homologous sequences, in virus 
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dose, in time after infection and a centrally positioned transgene in the viral genome 
elevates the targeting frequency. Limited packing ability of foreign DNA of 5 kb may 
restrict the applications of AAV vectors (HIRATA & RUSSELL, 2000; VASILEVA 
et al., 2006).  
3.4.2 Positive selection 
The efficiency of introduction of foreign DNA into the cell and, even more, the 
efficiency of integration of the foreign DNA into the genome are rare processes. In 
order to distinguish cells with stably integrated transgene from negative cells a 
selection strategy is needed. The easiest way is to insert a gene for antibiotic 
resistance as a positive selection cassette into the vector with all necessary elements 
for transcription, such as a promoter and a terminating polyadenylation signal. The 
promoter has to be active in the transfected cells, thus ubiquitous promoters such as 
the one of the phosphoglycerate kinase (PGK) gene are preferred to provide 
transcription of the selection gene in any transfected cell type (CHEAH & 
BEHRINGER, 2001). Frequently used positive selection markers are genes providing 
resistance to neomycin, blasticidin, puromycin or hygromycin (VAN DER WEYDEN 
et al., 2002). The selection cassette should generally be flanked by recognition 
sequences for site-specific recombinases, to provide a possibility to remove the 
selection cassette if necessary, as it may affect gene expression in and around the 
targeted locus (FIERING et al., 1995; PHAM et al., 1996). Recognition sites for Cre, 
FLPe or ϕC31 have been used regularly (SORRELL & KOLB, 2005). 
3.4.3 Negative selection 
Cells with integrated transgene are selected positively without differentiating between 
random or site directed insertion. However, a lot of cell clones have to be screened for 
positive integration in order to find a clone, which has undergone HR, as there are far 
more random integration events than HR events. To increase the number of cell clones 
with targeted mutation several different methods can be used. For positive-negative 
selection (PNS) a negative selection cassette, such as thymidine kinase or diphtheria 
toxin A, is placed in addition to the positive selection cassette outside of one or both 
of the homologous sequence of the linearized transgene (NAGY et al., 2003). In the 
case of HR the cassette is lost, otherwise the cell succumbs to the negative selection. 
PNS yields 2-10 fold enrichment for targeted clones compared to positive selection 
resistance alone. The low enrichment values may be caused by damage of the 
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sequence of the negative selection cassette (SORRELL & KOLB, 2005). Mario R. 
Capecchi, Sir Martin J. Evans and Oliver Smithies were awarded the Nobel Prize in 
2007 for their discoveries of principles for gene targeting in mice including the PNS. 
3.4.4 Gene trapping 
 Besides the less efficient selection cassette approaches, one can achieve a positive 
clone enrichment of up to 5000-10000 fold by using a promoter-trap selection method 
(HANSON & SEDIVY, 1995). In the promoter-trap selection the expression of a 
promoter-less resistance gene is depended on the targeted integration of the transgene 
as it is expressed under the gene’s own promoter (JASIN & BERG, 1988; SEDIVY & 
SHARP, 1989). It has to be kept in mind, that this selection strategy is only applicable 
for active genes. A similar strategy is the polyadenylation-trap selection, which is 
based on the absence of a polyadenylation signal for the resistance gene, making it 
also suitable for targeting of silent genes (THOMAS & CAPECCHI, 1987; 
DONEHOWER et al., 1992). 
Further approaches to optimize gene targeting frequencies include the attempt to shift 
the ratio between HR and NHEJ in order to increase HR compared to NHEJ by 
interfering with the expression of genes considered to play a role in these processes. 
Vasquez et al. give an overview of possible genes (VASQUEZ et al., 2001). Triplex 
forming oligonucleotides can also be used to stimulate HR. They are short nucleotide 
sequences binding sequence specific with a high affinity to purine-rich sequences in 
the major grove of the DNA double helix and form a triplex structure with the DNA, 
which induces repair mechanisms (reviewed in SEIDMAN & GLAZER, 2003). 
3.4.5 BAC vectors  
Besides enrichment by selection, there are several other attempts to increase targeting 
frequency, such as an increase in length of homologous arms. Like mentioned above 
this can be achieved by using alternative vectors like YACs, PACs and BACs. 
Compared to YACs, BAC and PAC vectors have been proven to be advantageous 
(COPELAND et al., 2001), thereof BACs being more commonly used. They are 
fertility-(F-) factor-based plasmid vectors, replicating in low copy numbers 
(HOSODA et al., 1990). BACs can generally contain genomic DNA inserts of about 
200 kb, but can accommodate far larger inserts (SHIZUYA et al., 1992). The length of 
the genomic inserts compared to conventional targeting vectors (generally up to 
20 kb) makes them suitable for various applications besides gene targeting. Genome 
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sequencing approaches, such as the porcine genome are based on BAC libraries, 
providing a map of the pig genome and making BAC sequences accessible for various 
gene loci (CHEN et al., 2007; HUMPHRAY et al., 2007). BACs have been applied in 
several other fields of research in the mouse, like identification of mutation or 
characterization of regulatory sequences and functions of genes in vivo. Sequences 
adjacent to genes of interest on BACs may include genomic regulatory segments. 
Therefore, genes can be expressed under their own regulatory elements independent of 
their integration site, yet dependent on copy number and endogenous gene expression 
(CHANDLER et al., 2007). BACs are stable and easy to handle (GIRALDO & 
MONTOLIU, 2001), however, genetic modifications were difficult to achieve and 
screening by ordinary methods such as PCR and Southern blot is not possible due to 
the long homologous arms (VALENZUELA et al., 2003). Establishment of phage 
based recombination in E. coli made the modification of BAC sequences feasible and 
thus enabled the application of BACs in gene targeting experiments. There are two 
commonly used methods: ET cloning and recombineering (COPELAND et al., 2001; 
ZHANG et al., 1998). ET cloning uses the RecET system derived from the prophage 
Rac. Recombination is induced by addition of L-arabinose. Recombineering is 
accomplished by Red recombinase derived from bacteriophage λ, induced by heat 
shock. The development of screening methods for positively targeted cell clones by 
large vectors like the real-time PCR based “loss-of-native-allele” assay and applying 
the FISH assay made screening in BAC targeting experiments viable 
(VALENZUELA et al., 2003; YANG & SEED, 2003; GOMEZ-RODRIGUEZ et al., 
2008). For the first time site-directed mutagenesis was successfully accomplished in 
murine ESCs (TESTA et al., 2003; VALENZUELA et al., 2003; YANG & SEED, 
2003) and later on also in human ESCs (SONG et al., 2010). Effective targeting 
efficacies of up to 28% could be observed (YANG & SEED, 2003).  
3.4.6 Designer nucleases 
Another approach to increase targeting frequencies is to induce artificial DSB at the 
desired locus for site-directed mutagenesis in the genome via designer nucleases and 
thus induce homologous recombination. Initially SceI, a homing endonuclease, was 
used to induce DSB and HR frequencies were greatly increased (ROUET et al., 1994; 
CHOULIKA et al., 1995). Yet SceI requires the introduction of its specific recognition 
sequence to the target locus before it can be applied, which makes it unsuitable for 
gene targeting experiments. Zinc finger nucleases (ZFNs) are artificial molecules 
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where the nonsequence-specific DNA cleavage domain of the FokI type II restriction 
endonuclease is fused to a sequence-specific zinc finger DNA binding domain 
(reviewed by PORTEUS & CARROLL, 2005).  ZFNs can be designed to target 
specific sequences and create DSB at desired loci. By offering a homologous donor 
substrate, rates for HR could be increased at the target loci in human cells and site 
directed mutagenesis could be achieved (URNOV et al., 2005). However, due to 
unspecific activity, ZFNs can generate random DSB in the cells’ genome and have a 
cytotoxic effect. Quite recently a novel designer nuclease (TALEN) has been 
established based on transcription activator-like effector (TALE) proteins isolated 
from plant pathogens Xanthomonas (CHRISTIAN et al., 2010). They are said to have 
a high nuclease activity combined with a lower cytotoxicity, compared to ZFNs 
(MUSSOLINO et al., 2011).   
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III. ANIMALS, MATERIAL AND METHODS 
1 Animals 
For the production of the DMD pigs, landrace mix gilts were used as embryo 
recipients. Furthermore, the produced DMD pigs were characterized and age, as well 
as weight matched pigs, were used as controls. All pigs were housed in planar stables 
with straw covered floor. The DMD piglets were fed with an artificial feeding system 
with commercial milk powder (Normi Porcinorm PIGI, Norlac) and after weaning 
with commercial food mixed with water. Control piglets were raised by their mothers 
and fed with commercial pig food after weaning. All animal experiments were carried 
out according to the German Animal Welfare Act (55.2-1-54-2531-86-10).  
2 Material 
2.1 Apparatuses 
Abi Prism 7000 Sequence detection system  Applied Biosystems, USA 
AccuJet® pro Pipetman    Brand Wertheim 
Agarose gel electrophoresis chamber  OWL Inc., USA 
Zeiss Axiovert 200 M fluorescence microscope Carl Zeiss, Oberkochen 
Centrifuges 5415 D, 5417 R, 5810R   Eppendorf, Hamburg 
Centrifuge Biofuge pico    Heraeus, Osterode 
Centrifuge Labofuge M     Heraeus, Osterode 
Centrifuge Rotanda 96    Hettich, Tuttlingen 
Chyo scales      YMC Co., Japan 
E.coli pulser electroporation device   BioRad, Munich 
Eppendorf HH Mastercycler Gradient  Eppendorf, Hamburg 
GeneAmp® PCR System 9700   Applied Biosystems, USA 
GeneQuant Pro spectrophotometer   Amersham, UK 
Gel documentation system     BioRad, Munich 
GFL 3031 shaker     Hilab, Düsseldorf 
Glass pipettes      Hirschmann, Eberstadt 
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Incubators      Memmert, Schwabach 
       Heraeus, Osterode 
Microscope DM IL     Leica, Wetzlar  
MS1 minishaker     IKA Labortechnik, Staufen 
Finnpipette® Multichannel pipet (300 µl)  Thermo Fisher Scientific, USA 
NucleofectorTM II      Lonza, Cologne 
Neubauer counting chamber    Assistent, Sondheim 
Microprocessor pH meter    WTW, Weilheim 
Pipettes      Gilson Inc., USA 
  Eppendorf, Hamburg 
Power Pac 300 gel electrophoresis unit  BioRad, Munich 
REAX2 Automatic swivel unit   Hilab, Düsseldorf 
RH Basic heating plate with magnetic stirrer IKA Labortechnik, Staufen 
Severin 900 microwave    Severin, Sundern 
SS35 50 ml centrifuge tubes    Eppendorf, Hamburg 
Steril benches Laminair® HB2448K, HB2472 Heraeus, Osterode 
Thermomixer 5436     Eppendorf, Hamburg 
Thermostat Plus     Eppendorf, Hamburg 
Vidoeplan image analysis system    Zeiss-Kontron, Munich 
Water bath sub14     Grant, UK 
WB6 water bath     Firmengruppe Preiss-Daimler, 
       Medingen 
2.2 Consumables 
ABgene® 96-well PCR plates   Thermo Scientific, Ulm 
Centrifuge tubes (15 ml, 50 ml)   Falcon®, Becton Dickinson, 
Heidelberg 
6-well, 96-well F-bottom culture dishes Cellstar® Greiner bio-one, USA 
Cultupe sterile culture tubes    Simport, Canada 
Culture dishes      Roth, Karlsruhe 
Cryotubes 1 ml     NuncTM, Denmark  
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Cryotubes 2 ml     Almeco, Denmark 
MicroampTM optical 96-well reaction plate  Applied Biosystems, USA 
MicroampTM optical adhesive film   Applied Biosystems, USA 
Parafilm®M      American Can Company,  
USA 
PCR reaction tubes (0.2 ml)    Braun, Wertheim 
Pipette tips      Eppendorf, Hamburg 
Pipette tips with filter     Axygen Inc., USA 
QIAtip 500      Qiagen, Hilden 
SafeGrip® Latex gloves    SLG, Munich 
Safe-Lock reaction tubes (1.5 ml, 2 ml)  Eppendorf, Hamburg 
Serological pipettes Cellstar®   Greiner bio-one, USA 
Steritop GP 0,22 µm Express®plus membrane Millipore, USA 
Sterivex GP 0,22 µm      Millipore, USA 
Tissue culture dishes (6 cm, 10 cm)   Sarstedt, Nümbrecht 
2.3 Chemicals 
All chemicals were used in p.a.-quality, if not stated otherwise. 
Acetic acid (glacial) (HOAc)    Merck, Darmstadt 
Agar-agar      Roth, Karlsruhe 
Agarose Universal     Bio&SELL, Nürnberg 
Agarose UltraPureTM     Invitrogen, Karlsruhe 
Amphothericin B     PAA, Austria 
Ampicillin      Roth, Karlsruhe 
Betain       Sigma-Aldrich, Steinheim  
Blasticidin, bla     PAA, Austria 
Bromophenolblue     Roth, Karlsruhe 
β-Mercaptoethanol      Sigma-Aldrich, Steinheim 
Chloramphenicol     Sigma-Aldrich, Steinheim 
Chloroform      Merck, Darmstadt 
Dimethylsulfoxid (DMSO)    Sigma-Aldrich, Steinheim 
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Doxycycline      Sigma-Aldrich, Steinheim 
Dithiothreitol (DTT)     Biomol, Hamburg 
Ethylenediaminetetraacetic acid (EDTA)  Roth, Karlsruhe 
Ethanol (EtOH)     Roth, Karlsruhe 
Ethidiumbromide      Merck, Darmstadt 
Geneticin (G418)     Invitrogen, Karlsruhe 
Glucose      Roth, Karlsruhe 
Glycerol      Roth, Karlsruhe 
Hydrochloric acid, 37% (HCl)   Roth, Karlsruhe 
Isopropyl-beta-D-thiogalactopyranoside (IPTG) Thermo Fisher Scientific, USA 
Isoamylalcohol (CiA)     Roth, Karlsruhe 
Kanamycin      Roth, Karlsruhe 
Magnesium chloride (MgCl2)   Merck, Darmstadt 
Mineral oil       Roth, Karlsruhe 
Polyethylenglycol (PEG) 8000   Roth, Karlsruhe 
Peptone/Tryptone     Roth, Karlsruhe 
Phenol       Roth, Karlsruhe 
Potassium acetate (KOAc)    Roth, Karlsruhe 
Potassium chloride (KCl)    Sigma-Aldrich, Steinheim 
di-Potassiumhydrogenphosphate (KH2PO4)  Roth, Karlsruhe 
2-Propanol      Roth, Karlsruhe 
Sodiumdodecylsulfate (SDS), ultrapure  Roth, Karlsruhe 
Sodium chloride (NaCl)    Roth, Karlsruhe 
Sodiumdihydrogenphophate-1-hydrate   Merck, Darmstadt 
(Na2HPO4+2H2O) 
Sodium hydroxide (NaOH)    Roth, Karlsruhe 
Sodium pyruvate     Invitrogen, Karlsruhe 
D(+)-Sucrose      Roth, Karlsruhe 
Tris-(hydroxymethyl)-aminomethan (Tris)  Roth, Karlsruhe 
TRIzol® Reagent     Invitrogen, Karlsruhe 
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Yeast extract      Roth, Karlsruhe 
5-Brom-4-chlor-3-indoxyl-β-Dgalactopyranosid  Roth, Karlsruhe 
(X-Gal) 
2.4 Enzymes, kits and other reagents 
2.4.1 Enzymes 
DNase I and buffer (10 ×)    Thermo Fisher Scientific, USA 
Herculase®II and buffer (5 ×)   Agilent, Böblingen 
Taq Polymerase and buffer (10 ×)   Agrobiogen, Hilgertshausen 
Proteinase K      Roth, Karlsruhe 
Restriction enzymes and buffer   Thermo Fisher Scientific, USA 
RevertAidTM H-Minus M-MuLV Reverse  Thermo Fisher Scientific, USA 
Transcriptase and buffer (5 ×) 
RiboLockTM RNase inhibitor and buffer (5 ×) Thermo Fisher Scientific, USA 
Ribonuclease A (RNase A)    Roche, Mannheim 
T4 DNA Ligase and buffer (10 ×)   Thermo Fisher Scientific, USA 
Uracil-DNA Glycosylase (UNG)   Thermo Fisher Scientific, USA 
2.4.2 Kits  
CloneJETTM PCR Cloning Kit   Thermo Fisher Scientific, USA 
E.Z.N.ATM Endo-free Plasmid Maxi Kit  Omega, USA 
Fermentas Midi Prep DNA    Thermo Fisher Scientific, USA 
AmaxaTM Basic NucleofectorTM Kit    Lonza, Cologne 
for Primary Mammalian Fibroblasts      
Qiaex® II Gel Extraction Kit    Qiagen, Hilden 
Qiagen Endofree Plasmid Kit   Qiagen, Hilden 
Absolutely RNA Nanoprep Kit   Agilent Technologies, USA 
2.4.3 Other reagents 
Arabinose      Thermo Fisher Scientific, USA 
BigDye® terminator v3.1    Applied Biosystems, USA 
6 × DNA loading dye     Thermo Fisher Scientific, USA 
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DNA molecular weight standards: 
Gene RulerTM 1 kb DNA Ladder   Thermo Fisher Scientific, USA 
pUC Mix Marker, 8     Thermo Fisher Scientific, USA 
dNTPs (dATP, dCTP, dGTP, dTTP)   Thermo Fisher Scientific, USA 
Oligo(dT)18 Primer     Thermo Fisher Scientific, USA 
Omega ETR Reagent      Omega, USA 
SYBR® Green PCR Mastermix    Applied Biosystems, USA 
2.5 Reagents for cell culture 
CollagenR      Serva, Heidelberg 
DifcoTM Trypsin 250      BD, USA 
Dulbecco Modified Eagle Medium (DMEM) Invitrogen, Karlsruhe 
Fetal calf serum (FCS)    Invitrogen, Karlsruhe 
L-Glutamine (200 mM)    PAA, Austria 
L-Glutamine + Penicillin/Streptomycin (100 ×) PAA, Austria 
Non-essential amino acids (100 ×)   Invitrogen, Karlsruhe 
2.6 Buffers, media and solutions 
Solvent was, if not stated otherwise, in a Millipore machine deionized water called 
aqua bidest. Media and Solutions used in cell culture were filtered sterile before use 
and stored on 4°C. FCS was inactivated by heating up to 56 °C for 30 minutes, filtered 
sterile and stored at −20 °C.  
Chloroform-isoamylalcohol (CiA) 
 96 ml chloroform 
 4 ml isoamylalcohol 
 Stored at 4 °C protected from light. 
Culture medium for porcine kidney cells 
 DMEM with 
10% or 15% (v/v) FCS 
 1% (v/v) Non-essential amino acids (100 ×) 
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 1% (v/v) Sodium pyruvate (100 ×) 
 1% (v/v) L-Glutamine (200 mM) + Penicillin/Streptomycin (100 ×) 
0.1 mM β-Mercaptoethanol 
Cryo medium  
 10% (v/v) DMSO  
 90% (v/v) FCS 
DNA loading buffer (10 ×) 
 10% glycerol in aqua bidest. 
 1 spatula tip of bromophenolblue 
 Add 0.5 M NaOH until colour turns blue 
 Stored at 4 °C. 
DNA molecular weight standards 
 100 µl pUC8 Mix Marker 8 or 1 kb DNA ladder standard 
 100 µl 6 × loading dye 
 400 µl aqua bidest 
 Stored at -20 °C 
dNTPs  
 2 mM or 10 mM respectively dATP, dCTP, dGTP, dTTP 
 Stored at -20 °C. 
LB medium 
 5 g yeast extract 
 10 g tryptone/peptone 
 2.5 g NaCl 
 Ad 1000 ml aqua bidest 
 pH 7.0 (adjust with 5 M NaOH) 
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 Autoclave 
 Stored at room temperature. 
LB-agar plates 
 5 g yeast extract 
 10 g tryptone/peptone 
 5 g NaCl 
 pH 7.0 (adjust with 5 M NaOH) 
 15 g agar-agar 
Autoclave 
Cool down to 60 °C 
Add 1 ml respective antibiotic (ampicillin 50 mg/ml, chloramphenicol 
12.5 mg/ml, kanamycin 25 mg/ml)  
Pour into culture dishes 
Stored at 4 °C. 
Lysisbuffer for DNA isolation (High salt precipitation) 
 100 µl PK buffer (1 ×) 
 10 µl SDS (10%) 
 4.4 µl DTT (1M) 
Lysisbuffer for DNA isolation (PCiA extraction) 
 160 mM Saccharose 
80 mM EDTA pH 8.0 
100 mM Tris/HCl pH 8.0 
0.5% (w/v) SDS 
Phosphate-buffered saline without Calcium and Magnesium (PBS) 
 8 g NaCl 
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 0.2 g KCl 
 0.2 g KH2PO4 
 2.14 g Na2HPO4+7H2O 
 Ad 1000 ml aqua bidest 
 pH 7.2-7.4 
 Stored at room temperature. 
Phenol-chloroform-isoamylalcohol (PCiA) 
 25 ml phenol 
 25 ml CiA 
 Stored at 4 °C, protected from light. 
PEG-MgCl2 
 40% (w/v) PEG 8000 
 30 mM MgCl2 
 Stored at room temperature. 
PK buffer (10 ×) 
 200 mM Tris 
 1 M NaCl 
 40 mM EDTA 
 Stored at room temperature. 
Plasmid A 
 50 mM glucose 
 25 mM Tris/HCl pH 8.0 
 10 mM EDTA/NaOH pH 8.0 
 Stored at room temperature. 
Plasmid B 
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 0.1 M NaOH 
 0.5% (w/v) SDS 
 Prepared freshly before each use. 
Plasmid C 
 3 M KOAc 
 pH 4.8 with 9 M HOAc 
 Autoclave 
 Stored at room temperature. 
Proteinase K 20 mg/ml 
 Stored at 4 °C 
RNaseA 20 mg/ml 
 Stored at −20 °C 
Selection medium with G418 100 mg/ml 
 Culture medium with  
1.2 mg/ml G418  
Sequencing buffer (5 ×) 
 17.5 ml 1 M Tris/HCl (pH 9.0) 
 125 µl 1 M MgCl2 
 Ad 50 ml aqua bidest 
 Stored at -20 °C. 
Starvation medium 
 DMEM with 
0.5% (v/v) FCS 
 1% (v/v) Non-essential amino acids (100 ×) 
 1% (v/v) Sodium pyruvate (100 ×) 
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 1% (v/v) L-Glutamine (200 mM) + Penicillin/Streptomycin (100 ×) 
STE  
 10 mM Tris/HCl pH 8.0 
 100 mM NaCl 
 1 mM EDTA/NaOH pH 8.0 
 Stored at room temperature. 
Stop Medium  
 10% (v/v) FCS 
 90% (v/v) DMEM 
T-buffer 
 10 mM Tris 
 Adjust to pH 8.0 with HCl 
 Stored at room temperature. 
TAE (50 ×) 
 242 g Tris 
 100 ml 0.5 M EDTA (pH 8.0) 
 57 ml AcOH 
 Ad 1000 ml aqua bidest 
 Stored at room temperature and diluted to respective concentration prior to 
use. 
Trypsin/EDTA 
 PBS without calcium and magnesium with 
 0.5% (w/v) Trypsin 
 0.04% (w/v) EDTA 
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2.7 Oligonucleotides 
Oligonucleotides were either designed by hand or with the primer 3 software. They 
were manufactured by Thermo Fisher Scientific, USA. 
DMD3BNf  5'-ATGGATCCGCGGCCGCAAACTGGAACCACAAGAC-3' 
DMD3KPr  5'-ATGGTACCTTAATTAATCTGCTCTCTGGTCACTC-3' 
DMD5BNPr  5'-TGGATCCTCGCGACTGCAGCCTTAGAAG 
CAGTCTCCTTC-3' 
DMD5SPf  5'-ATGAGCTCTTAATTAAGGTGTTCTCTCCTCTATG-3' 
DMDexBr  5'-GTAGATCTAAGTACCACTGCATACAGGAG-3' 
DMDexSf  5'-GAGTCGACCCATCTACCACATTTCACCTC-3' 
DMDsc1f  5'-CTGGTATGAGCACCAGATTG-3' 
DMDkosc2r  5'-GGACAGGTCGGTCTTGACAA-3' 
DMDwtsc1r  5'-ATAGGTCTCAAGGTACTGTG-3' 
DMD-int51-MSf1 5'-CAGTTAGGAACTGCTGGTAG-3' 
DMD-int-MSr1 5'-TGTCAGTCATTGAGCTAGTCAC-3' 
DMDFLPeTest3fw 5'-AATCTGCTCTCTGGTCACTC-3' 
DMDFLPeTest5rv 5'-TCTATGGATGGCTCAGTGGA-3' 
FLPeSf  5'- ATGTCGACCACCATGAGCCAATTTGA-3' 
FLPeXr  5'-CATCTAGATATCACAGATCTTCTTCAG-3' 
FLPf1   5'-AAGCATCTGGGAGATCACTG-3' 
FLPf2   5'-GGAACTCTGAACCAGTCCTA-3' 
FLPr1   5'-CAGTGATCTCCCAGATGCTT-3' 
FLPr2   5'GTATATGTGCCTACTAACGC-3' 
EM7r   5-TGCTCCATGGTTTAGTTCCTCACCTTG-3 
M13   5'-GGAAACAGCTATGACCATG-3' 
T7   5'-GTAATACGACTCACTATAGG-3' 
pJETforward  5'-CGACTCACTATAGGGAGAGCGGC-3' 
pJETreverse  5'-AAGAACATCGATTTTCCATGGCAG-3' 
neokanf  5'-GACAATAGCAGGCATGCTG-3' 
neokanR  5'-GTGGATGTGGAATGTGTGC-3' 
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neof   5'-TGATTCCCACTTTGTGGTTC-3' 
blaf   5'-CCATGGCCAAGCCTTTGTC-3' 
bla241r  5'-TTCCGATCGCGACGATACAAGTCAG-3'   
bla343r  5'-GTGAGGAAGAGTTCTTGCAGCTC-3' 
rTAf   5'-AGAAGCTTGGTGTAGAGCAG-3' 
rTAr   5'-CGTCTAAGTGGAGCTCGTC-3' 
TAREf1  5'-CTCGTTTAGTGAACCGTCAGATC-3' 
TAREf2  5'-GTATGTCGAGGTAGGCGTGTAC-3' 
CAGf   5'-CTCTGCTAACCATGTTCATG-3' 
CAG1377f  5'-GGTAATCGTGCGAGAGG-3' 
CAGex1f  5'-CTGACTGACCGCGTTACT-3' 
27G20f2  5'-GATACAAGGATGTGGTAGTCTAG-3' 
9G11f2  5'-CATCTATCCGGACAAAGCTCTAC-3' 
BACr1  5'-GTACTGATTCAGTCAGGGTTTCTG-3' 
BACr2  5'-CAGAGTTCACACACTGGAGAC-3' 
qPCRDMD11fw 5'-TGCACAATGCTGGAGAACCTCA-3' 
qPCRDMD12rv 5'-GTTCTGGCTTCTTGATTGCTGG-3' 
qPCRDMD5fw 5'-CAGCAGCAGTCAAAGGGCATA-3' 
qPCRDMD9rv 5'-AGGCAAGTCTGGGAAGCATCA-3' 
GGTA3423fw 5'-TCATCAGTGGATTCACCCCAA-3' 
GGTA3640rev 5'-CACCACGGGAATGCCTTC-3' 
HPRT834i2fw 5'-TGTCTGCGACCCACACCA-3' 
HPRT987i2rev 5'-GCATGCATCAGTAAGGAACTGG-3' 
PACT954f  5'-CGCTCGTGGTCGACAACG-3' 
PACT1919r  5'-CTGGATGGCCACGTACATG-3' 
Cs3f    5'-AACGTTAACGCGAACCCAGCTAG-3' 
Cs3r   5'-CCTCTTTCCTGGGCAGGTGTCCTTC-3' 
Ad-SB53  5'-TCGACGTTCGATGACCAGTGGTCCAGC-3' 
Ad-SB35  5'-TTAAGCTGGACCACTGGTCATCGAACG-3' 
AdK53E  5'-ATGATCTAGGTACCACGACGC-3' 
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AdK35E  5'-AATTGCGTCGTGGTACCTAGATCATGTAC-3' 
AdA53LN  5'-CGCGCCATAACTTCGTATAATGTATGCTATACGA 
AGTTAT-3' 
AdA35LN  5'-CTAGATAACTTCGTATAGCATACATTATACGAAG 
TTATGG-3' 
FRT53   5'-CGAGAAGTTCCTATACTTTCTAGAGAATAGGAAC 
TTCGAATTCAGGTCCTTAAGCTCCAGTCGACGGATC 
CTACTGGCGCGCCTACTATCAATTGGAAGTTCCTAT 
ACTTTCTAGAGAATAGGAACTTCGC-3' 
FRT35   5'-GGCCGCGAAGTTCCTATTCTCTAGAAAGTATAGG 
AACTTCCAATTGATAGTAGGCGCGCCAGTAGGATCC 
GTCGACTGGAGCTTAAGGACCTGAATTCGAAGTTCC 
TATTCTCTAGAAAGTATAGGAACTTCTCG-3' 
2.8 BACs and plasmids 
BACs:       BACPAC, CHORI, USA 
CH242-9G11    
CH242-27G20 
CH242-520G21 
CH242-284A18     
pBluescript II SK (−)     Thermo Fisher Scientific, USA 
pGEM®-T Easy Vector (5ng/µl)   Promega, USA 
2.9 Bacterial strains 
SW106      NCI Frederick, USA 
DH10B      New England Biolabs, USA 
TOP10      Invitrogen, Karlsruhe 
2.10 Software 
Abi Prism 7000     Applied Biosystems, USA 
BioEdit Sequence Alignment Editor   Ibis bioscience, USA 
Double Digest TM     Thermo Fisher Scientific, USA 
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FinchTV Version 1.3.1    Geospiza Inc., USA 
Macromedia Freehand MX    Adobe, USA 
NEBcutter V2.0       New England Biolabs, USA 
OligoAnalyzer 3.1     IDT Inc., USA 
Primer 3      Whitehead Institute for 
Biomedical Research, USA 
3 Methods 
3.1 Molecular genetic protocols 
During the establishment of a DMD pig model several molecular genetic standard 
protocols were applied regularly. These protocols are listed below. Aberrations or 
modifications are specified at the appropriate step in the procedures. 
3.1.1 PCR 
3.1.1.1 End-point PCR 
PCR reactions were performed in 0.2 ml reaction tubes and prepared at room 
temperature. Standard composition of PCR reaction mix for Taq-Polymerase and 
Herculase II with an end volume of 25 µl was: 
Taq-Polymerase Herculase II 
	  2.5 µl  5 µl  10 × PCR buffer 
2.5 µl   - MgCl2 (15 mM) 
2.5 µl  2.5 µl  dNTPs (2 mM) 
0.5 µl  0.5 µl  Primer forward (10 µM) 
0.5 µl  0.5 µl  Primer reverse (10 µM) 
0.2 µl  0.2 µl  Taq-Polymerase (5 U/µl) 
1 µl 1 µl DNA 
15.3 µl  15.3 µl  Aqua bidest 
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Standard cycler protocol was:  
4 min 95 °C Denaturation 
 30 sec 95 °C Denaturation 
 30 sec X °C Annealing 
 Y min 72 °C Elongation 
 Go to step 2 34 × 
   10 min 72 °C  Elongation 
 15 min 4 °C Termination 
 
Depending on the reaction sequence specific primers were used. Primer pair specific 
approximate values for X were calculated by the 4 + 2 rule (2 °C for each A and T, 
4 °C for each G and C, value − 5). Depending on the amplicon length Y is calculated 
with 2 kb/min.  
3.1.1.2 qPCR 
The standard curve was prepared beforehand from DNA of Niere m cells, which was 
isolated via PCiA extraction (3.1.7.1). The values for copy numbers of the standard 
curve were assigned to 10000, 7500, 5000, 2500, 500, 250, 50 and 25, assuming that 
100 ng of DNA equates 15000 DNA copies. For each standard curve a calibrator was 
prepared from the same initial DNA. DNA for qPCR screening was isolated by high 
salt precipitation (3.1.7.1). Samples, standard curve and reaction components were 
warmed to room temperature, except for UNG, which was stored at − 20°C. The 
reaction was pipetted on ice and carried out in MicroampTM optical 96-well reaction 
plates. For each set of samples three plates were prepared, one primer pair on one 
plate. All samples were run as doublets, except for the calibrator, which was run in 
triplets and the non template control (ntc), as a single sample. The position of the 
samples was identical on each plate. The reaction mix was composed as follows: 
 
GGTA HPRT DMD 
SYBR green 6.25 µl 6.25 µl 6.25 µl 
UNG 0.075 µl 0.075 µl 0.075 µl 
Primer forward (5 µM) 0.75 µl 0.25 µl 0.5 µl 
Primer reverse ( 5µM) 0.75 µl 0.25 µl 0.5 µl 
Template 2.5 µl 2.5 µl 2.5 µl 
Aqua bidest 2.175 µl 3.175 µl 2.675 µl 
 
The layout of the plates stayed always the same. The standard curve samples were 
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located on the left and the three calibrator samples and the non template control (ntc) 
were placed on the right bottom. After filling, plates were closed with a MicroampTM 
optical adhesive film and either run immediately or stored at − 20°C.  
Reaction took place in an ABI Prism 7000 Sequence detection system with following 
cycler protocol: 
2 min  50 °C UNG activation 
10 min 95 °C Polymerase activation 
15 sec 95 °C Denaturation 
1.30 min 63 °C Annealing and elongation 
Repeat steps 3 and 4 39 × 
 
After the last cycle, the plates were again heated from 60 °C to 95 °C in order to 
obtain a dissociation curve of the PCR products. 
3.1.2 Agarose gel electrophoresis 
DNA fragments were separated according to their size via agarose gel electrophoresis. 
Agarose gels were prepared by heating 1× TAE buffer with 0.7% or 2% agarose 
respectively in a microwave until agarose was completely melted. After cooling down 
to approximately 60 °C ethidiumbromide (0.5 µg/ml) was added, the gel was poured 
into a gel electrophoresis chamber with an appropriate comb. After curing the 
chamber was filled with 1×TAE. DNA loading buffer (1/10 volume) was added to the 
DNA samples. The samples and a molecular weight standard were loaded into the gel 
slots and an electric current was applied. Bands were visualized by UV-light and 
pictures were taken (BioRad). The DNA fragments were characterized by comparison 
with the molecular weight standard.  
If fragments were to be further processed, agarose UltraPureTM was used and 
fragments were cut out of the gel under UV light control. Otherwise Universal agarose 
was used for gel preparation. 
3.1.3 Elution 
After agarose gel electrophoresis DNA fragments were excised and eluted out of the 
agarose gel for subsequent processing with the Qiaex® II Gel Extraction Kit 
according to the manufacture’s protocol.   
In order to determine the concentration of the eluate, 3 µl were mixed with 15 µl aqua 
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bidest and 2 µl DNA loading buffer and loaded onto a 0.7% agarose gel, together with 
a molecular weight standard. For concentration determination band intensity was 
compared to the molecular weight standard.  
3.1.4 Restriction digest 
Plasmids and BACs were digested with restriction enzymes (generally 10 IU/µl) either 
for subsequent ligation or for analysis. Restriction enzyme recognition sites could be 
identified using NEBcutter V2.0. Appropriate suggestions for reaction conditions for 
desired enzyme combinations were obtained from DoubleDigestTM. For analysis 
approximately 1 µg of DNA was digested, for subsequent ligation at least 2 µg of 
DNA were digested. Generally 1 unit of restriction enzyme was used per 10 µl 
reaction mix. Restriction digests were incubated overnight at 37 °C. 
If the digest was only used for qualitative analysis, the samples were loaded onto an 
agarose gel directly. If the DNA fragments were afterwards used for ligation, they 
were extracted with PCiA and purified before gel separation. The reaction volume was 
adjusted to 150 µl with aqua bidest and 100 µl PCiA was added. The mixture was 
shaken for 1 min and subsequently centrifuged for 3 min at 16100 × g. The aqueous 
supernatant was transferred into a new 1.5 ml reaction tube. 15 µl 3 M NaOAc and 
400 µl EtOH 100% (cooled to −20 °C) were added. Samples were placed at −80 °C 
for 30 - 60 min. Afterwards they were centrifuged for 30 min at 18100 × g, the 
supernatant was removed and the DNA pellet was air dried for 6 min. It was then 
resolved in 20 µl T-buffer. 
After PCiA purification the samples were loaded onto an ultra-pure Agarose gel with 
an appropriate concentration and the desired band was cut out and eluted. 
The BAC targeting vector was linearized prior to nucleofection with SfiI in following 
reaction mix: 
X µl  Targeting vector (20 µg) 
2 µl  SfiI (10 IU/µl) 
6 µl Buffer Green 
Ad 60 µl Aqua bidest 
 
The reaction mix was incubated at 50 °C overnight and was covered with mineral oil. 
On the next day the DNA in the reaction mix was purified with PCiA and solved in 
25 µl T-buffer.  
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3.1.5 Ligation 
Eluted DNA fragments, either PCR products or fragments of digestion, were ligated 
into a respective vector with the T4 DNA Ligase. After determination of the 
concentration (see 3.1.3) of vector and fragment, they were added in equal amounts to 
the reaction mix. 20 µl of the reaction mix were composed as follows: 
X µl  Vector DNA (100 ng) 
Y µl  Insert DNA (PCR product or restriction digest fragment) 
1 µl  T4 DNA ligase 
2 µl  10× Ligation buffer   
Ad 20 µl  Aqua bidest 
Y: Amount of insert DNA is dependent on the vector DNA; it was stoichiometric equally 
added into the reaction mix 
 
The reaction was left at room temperature for at least 4 h and was subsequently 
terminated by heating the samples at 65 °C for 15 min. 
3.1.6 Heat shock transformation 
In order to multiply plasmids in high copy numbers with rare mutational events, they 
were brought into competent E.coli, strain TOP10 via heat shock transformation. Heat 
shock competent cells were thawed up on ice and DNA added: 9 µl of plasmid DNA, 
which has been ligated prior to transformation or 1 µl of undiluted isolated plasmid 
DNA and 1 µl of 1/1000 diluted isolated plasmid DNA and mixed carefully. Samples 
were placed on ice for 20 min and subsequently heated at 42 °C for 45 sec. They were 
then placed on ice for 2 min. Afterwards 1 ml LB medium was added followed by 
incubated at 37 °C for 45 min. Eventually samples were centrifuged for 5 min at 
2300 × g and the pellet was resuspended in 100 - 200 µl of the supernatant and plated 
on LB agar plates with appropriate selection medium (ampicillin 50 µg/ml, kanamycin 
25 µg/ml and chloramphenicol 12.5 µg/ml). If pGEM®-T Easy Vector was used LB 
agar plates were treated before use with 40 µl IPTG (100 mM) and X-Gal (20 mg/ml 
in Dimethylformamide) for differentiation of positive and negative plasmid colonies. 
The agar plates were incubated at 37 °C overnight. After counting colonies, plates 
were wrapped airproof in Parafilm®M and stored at 4 °C until further processing.  
3.1.7 DNA isolation 
Different protocols were used for DNA isolation according to the type of sample the 
DNA was isolated from or the purpose for which the DNA was isolated. After 
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isolation DNA concentration was measured with the GeneQuant Pro spectrometer at a 
wavelength of 260 nm by adding 5 µl DNA to 95 µl aqua bidest (1:20 dilution). 
Samples were stored at 4 °C if used frequently. Otherwise they were stored at −20 °C.  
3.1.7.1 Isolation of genomic DNA 
Two different protocols were used for DNA isolation from tissue samples or cell 
pellets. High salt precipitation was applied when DNA was used in qPCR. For other 
applications DNA was isolated via PCiA extraction. For the PCiA extraction the tissue 
samples were cut into small pieces (about 1 g, 5 × 5 × 5 mm3) and 400 µl lysis buffer 
for DNA isolation and 20 - 30 µl ProteinaseK were added. The samples were mixed 
and incubated at 60 °C overnight. When the tissue pieces were completely digested, 
the samples were centrifuged at 16100 × g for 5 - 6.5 min and the supernatant was 
transferred into a new reaction tube. First 400 µl of 4.5 M NaCl were added, then 
600 µl PCiA and the samples were shaken for 1-2 min by hand or for 10 min on an 
automatic shivel. Afterwards they were centrifuged for 5 - 6.5 min at 16100 × g and 
the supernatant was transferred to a new reaction tube. The steps of adding PCiA, 
shaking, centrifugation and transfer into a new tube were repeated twice. Then 
2-propanol (2/3 volume of supernatant) was added and the DNA precipitated. The 
DNA pellet was transferred twice into a new reaction tube with 600 µl 70% EtOH and 
was then left in the second tube overnight at 4 °C. The 70% EtOH was removed and 
the DNA pellet was air dried for 6 min and resolved in 55 µl T-buffer. DNA was then 
left overnight at 4 °C or at 50 °C for 10 min before concentration was measured. 
DNA from single wells of 96-well cell culture plates was isolated using the high salt 
precipitation protocol. 114.4 µl of the lysisbuffer for DNA isolation by high salt 
precipitation were added to the cell pellet and the samples were incubated at 60 °C for 
60 min. 2 µl ProteinaseK were added, followed by incubation at 60 °C. After 60 min 
30 µl NaCl (4.5 M) were added, samples placed on ice immediately and subsequently 
centrifuged at 16100 × g for 20 min. The supernatant was transferred into a new 
reaction tube, 103 µl of 2-propanol was added and the reaction tubes were shaken 
carefully. They were then centrifuged at 16100 × g for 20 min, supernatant was 
removed and 500 µl 70% EtOH was added. DNA pellets in 70% EtOH were stored at 
4 °C overnight. The next day the samples were shaken carefully and centrifuged at 
16100 × g for 20 min. The supernatant was removed and the DNA pellets were air 
dried for 6 min. They were then resolved in 35 µl T-buffer and left at 55 
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1 h.  
3.1.7.2 Isolation of plasmid and BAC DNA 
Plasmid and BAC DNA used for analysis was isolated with a plasmid preparation 
protocol. If high quantities were needed a midi prep was done with a tripled volume. 
For multiplication single colonies of bacterial strains carrying the desired plasmids or 
BACs were inoculated in 5 ml LB medium with the appropriate antibiotic (ampicillin 
50 µg/ml, kanamycin 25 µg/ml and chloramphenicol 12.5 µg/ml) and unless indicated 
otherwise grown with shaking at 37 °C overnight. From the overnight cultures 
glycerol stocks were made by mixing 900 µl 60% glycerol with 300 µl overnight 
culture. They were stored at −80°C.  
If the overnight cultures were used for PCR screening 10 µl were mixed with 20 µl 
T-buffer and heated at 95 °C for 10 min. Afterwards the reaction mix was cooled 
down to 4 °C and centrifuged at 2300 × g for 5 min. 1 µl from the supernatant was 
used as template in the PCR.  
For the preparation of larger scales of plasmids or BACs, overnight cultures were 
centrifuged at 1300 × g for 10 min and the supernatant discarded. Pellets were 
resuspended in 750 µl STE buffer and transferred into a new reaction tube. Samples 
were again centrifuged at 4500 × g and the supernatant discarded. Pellets were 
resuspended in 200 µl Plasmid A and 400 µl of Plasmid B. was added. The samples 
were mixed gently by turning 7 times and placed on crushed ice for 5 min. 300 µl of 
Plasmid C was added, the samples again gently mixed and placed on ice for 3 min. 
After cooling they were centrifuged for 10 min at 16100 × g. The supernatants were 
transferred into new reaction tubes, 4 µl RNaseA added and were left at 37°C for 
45 min. Afterwards 300 µl PCiA was added and samples shaken for 1 min, 
centrifuged for 2.5 min at 16100 × g. After transfer of the aqueous phase to a new 
reaction tube, 650 µl of 2-Propanol was added. The precipitated DNA was pelleted by 
centrifugation at 16100 × g for 10 min. The supernatant was discarded, 700 µl 70% 
EtOH added and the DNA pellets was left in 70% EtOH either overnight or for a few 
hours. Afterwards the samples were centrifuged at 16100 × g for 2.5 min and the 70% 
EtOH discarded. The DNA pellet was air dried for 6 min and resolved in 55 µl 
T-buffer. 
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3.1.7.3 Endotoxin free isolation of DNA 
Plasmid DNA was isolated endotoxin free using the E.Z.N.A.TM Endo-free Plasmid 
Maxi Kit following the manufacturer’s protocol.  
For the endotoxin free isolation of BAC DNA a protocol, established by Katrin Krähe 
in our lab, with the combination of the Endofree Plasmid kit (Qiagen), the ETR 
Reagent (Omega Biotech) and QIAtip 500 columns (Qiagen), was applied. Bacterial 
strains carrying the desired BAC were inoculated in 3 ml of LB medium with 
chloramphenicol (12.5 µg/ml) and left at 32 °C (SW106) or 37 °C (DH10B) 
respectively for 5 h. In the evening the pre-culture was inoculated in 200 ml LB 
medium with chloramphenicol (12.5 µg/ml) overnight culture and left shaking at 32°C 
or 37°C respectively. In the morning the overnight culture was centrifuged at 4600 × g 
for 15 min at 4 °C. The supernatant was decanted; the pellet resuspended in 10 ml P1 
solution (+RNase). 10 ml of solution P2 were added and the samples left at room 
temperature for 5 min. Then 10 ml of solution P3 (pre-cooled on ice) were added and 
samples left on crushed ice for 15 min. They were then centrifuged for 40 min at 
17000 × g at 4 °C and the supernatant transferred into a new 50 ml falcon tube. 
Approximately 3 ml (1/10 of the volume) Omega ETR Reagent was added, the 
reaction mix turned 7 times and placed on crushed ice for 10 min. It was then split 
onto two 15 ml Falcon tubes and incubated at 42 °C for 15 min. The samples were 
again centrifuged at 5000 × g for 10 min at room temperature and the supernatant was 
transferred to a new 50 ml Falcon tube. Half of the volume of the supernatant 100% 
EtOH was added and the samples were incubated for 2 min at room temperature. In 
the mean time QIAtip 500 columns were equilibrated with 10 ml QBT solution. The 
samples were transferred onto a QIAtip 500 column and let run through. After the 
column was washed twice with 30 ml QC solution, the DNA was eluted with 15 ml 
QF solution into a 50 ml Falcon tube. 10.5 ml 2-Propanol were added, the samples 
divided onto two 15 ml Falcon tubes and centrifuged at 13900 × g for 40 min at 4 °C. 
The supernatant was discarded and the DNA pellet washed with 5 ml 70% EtOH 
ideally overnight at 4 °C. The pellets were resolved in 25 µl T-buffer. 
3.1.8 Recombineering and Cre mediated recombination 
For recombineering (COPELAND et al., 2001) and Cre mediated recombination 
SW106 E.coli strains were used (LIU et al., 2003). Apart from that BACs were kept in 
DH10B E.coli strains and plasmids in TOP10 E.coli strains. The SW106 strain carries 
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a fragment of a λ prophage, which contains the genes exo, bet and gam transcribed 
from the λPL promoter. The promoter is under the control of the repressor cI857. At 
32 °C the expression is repressed and at 42°C transcription from the exo, bet and gam 
genes recombination proteins is activated. SW106 cells were therefore never exposed 
to temperatures exceeding 32 °C, except when activation of the recombination 
proteins was desired. The exo protein is a 5’-3’ exonuclease, which produces single 
stranded overhangs at linear DNA fragments. The bet protein stabilizes the single 
stranded overhangs and plays an assisting role in the recombination process. The gam 
protein protects the introduced linear DNA fragments from degradation through the 
E.coli RecBCD protein. Introduction of linear DNA fragments with a homology to 
DNA molecules in the SW106 cells in the presence of the recombination proteins 
leads to recombination between the homologous sequences of the DNA molecules.  
SW106 cells are also capable of arabinose induced Cre mediated recombination as 
they contain a Cre gene under the control of an arabinose inducible promoter. Similar 
to the above described procedure a given plasmid or BAC is modified after its 
introduction in SW106 cells, activation of the Cre gene and electroporation of a linear 
modification fragment. In contrast to the λ prophage mediated recombination, which 
allows recombination between any homologous sequence, Cre recombinase 
exclusively mediates recombination between palindromic loxP sites.  
For their respective application they were prepared beforehand with following 
protocols (according to Recombineering protocols 
http://web.ncifcrf.gov/research/brb/protocol.aspx).  
3.1.8.1 Preparation of electro-competent cells 
Cultures of SW106 or DH10B cells were grown in LB medium without antibiotic, as 
they do not contain a resistance gene. If they contained a plasmid or BAC, either 
ampicillin (50 µg/ml) or chloramphenicol (50 µg/ml) respectively was added. A 5 ml 
overnight culture of the desired bacterial strain was inoculated and transferred the next 
day into a larger volume of LB medium (1 ml overnight culture per 100 ml). They 
were grown until they reached a certain OD value. For the preparation of conventional 
competent cells they were grown at 32 °C until they reached an OD600 of 0.6 – 0.8. 
Competent cells for recombineering were grown until 0.4 – 0.5 at 32 °C and then 
transferred to a 42 °C waterbath where they were kept for 15 min under continuous 
shaking. Competent cells for Cre mediated recombination were grown at 32 °C until 
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0.3 – 0.4. Then arabinose (100 mg/ml) was added and the cells shaken at 32 °C for 
one additional hour. After these individual procedures for conventional, arabinose 
induced as well as heat induced cells, the same washing procedure was used, during 
which cells were kept at 4 °C. The cell suspension was cooled down with occasional 
shaking for 10 min. Cells were then harvested by centrifugation for 10 min at 
1700 × g at 4 °C. The supernatant was carefully removed and the cell pellet 
resuspended in 50 ml ice-cold aqua bidest. Cells were again pelleted by centrifugation 
for 10 min at 1700 × g on 4 °C. The supernatant was removed and cells resuspended 
in 20 ml ice-cold aqua bidest. Cells were again pelleted by centrifugation for 10 min at 
1700 × g at 4 °C and the supernatant removed. The cell pellets were resuspended in 
5 ml ice-cold 10% glycerol and again centrifuged for 10 min at 1700 × g at 4 °C. The 
supernatant was removed and the cells resuspended in 1 ml ice-cold 10% glycerol. 
Aliquots of 50-80 µl were made and stored at −80 °C or used directly. 
3.1.8.2 Electroporation  
Aliquots of respective SW106 or DH10B competent cells were used for 
electroporation with the BioRad E.coli pulser electroporation device. The DNA was 
mixed with aliquot of electro-competent cells, transferred to precooled cuvettes and 
pulsed at 1.75 kV. 1 ml LB medium was added to the cuvette, mixed with the cells 
and then transferred to a 1.5 ml reaction tube. Cells were incubated at 32 °C for 
45 min in LB medium to introduce a plasmid or BAC into DH10B or SW106. If 
modifications either by λ prophage or Cre recombinase were desired, electroporated 
cells were kept for 2 h at 32 °C without antibiotic treatment. After the recovery and 
modification phase, cells were centrifuged at 2300 × g for 5 min, most the supernatant 
was removed, except for 100-200 µl and the cells resuspended in the remaining 
supernatant. Subsequently the cells were plated on LB agar plates with the appropriate 
antibiotic. 
3.1.9 Sequencing 
DNA sequencing was accomplished by capillary sequencing at the Helmholtz Center 
Munich. Plasmids were purified for sequencing by PEG precipitation. 20 µl aqua 
bidest and 20 µl PEG-MgCl2 were mixed with 20 µl plasmid. The mix was then 
equilibrated 10 min at room temperature, centrifuged 20 min at 16100 × g and the 
supernatant discarded. The DNA pellet was washed with 100 µl 70% EtOH overnight. 
Afterwards samples were centrifuged for 2 min at 16100 × g, the supernatant was 
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discarded and the DNA pellet air died for 6 min and resolved in 20 µl T-buffer. 
Afterwards DNA concentration was determined (see 3.1.7). In order to obtain best 
sequencing results DNA amount in nanogram used in sequencing reaction was 
calculated by following formula:  
DNA amount (ng) = the length of sequence, which is to be sequenced ⁄ 100 × 1.5 
DNA samples were diluted with aqua bidest to the desired concentration. For 
fragments ligated into a pGEM vector, pGEM specific primers T7 and M13 were used 
as standard primers and pJETforward and pJETreverse for plasmids with a PJET 
vector backbone. Additionally DNA fragment specific primers were used.  
Sequencing reaction mix was prepared in 0.2 ml reaction tubes at room temperature 
with a final volume of 10 ml. Reaction composition: 
4 µl  5 × sequencing buffer 
1 µl BigDye (keep on ice) 
1 µl  Primer (10 µM) 
2 µl Template 
2 µl Aqua bidest 
 
Cycler protocol for sequencing: 
1 min 95 °C denaturation 
5 sec 95 °C denaturation 
10 sec 50 °C annealing 
4 min 60 °C elongation 
Repeat steps 2 to 4 39 × 
 
The samples were purified via EtOH precipitation after the sequencing PCR reaction. 
First 2.5 µl 125 mM EDTA, followed by 30 µl 100% EtOH (cooled to −20 °C), were 
added. The samples transferred to new 1.5 ml reaction tube, incubated on ice for 
15 min and centrifuge for 30 min at 16100 × g at 4 °C. The supernatant was discarded 
and the pellet washed in 50 µl 70% EtOH. The samples were again centrifuged for 
2.5 min on 16100 × g, the supernatant was discarded and the pellet was air dried for 
6 min. Afterwards the pellet was resolved in 30 µl aqua bidest and transferred to a 
sequencing plate (ABgene® 96-well PCR plates). Sequencing plates were stored at 
−20 °C before transferring them to the Helmholtz Center Munich. Sequencing results 
were analyzed with the software FinchTV Version 1.3.1 and sequences copied to 
III. Animals, Material and Methods   
 51 
BioEdit for alignments and further comparison.  
3.2 Cell culture 
A primary cell line “Niere m“ established by Dr. Annegret Wünsch was used for 
transfection experiments. Cells were isolated from the kidney of a 3 months old male 
Landrace pig. Minced tissue was digested with Collagenase II. The Niere m is a mixed 
cell population of cells with fibroblast-like and epithelial-like morphology. The 
karyotype, nuclear transfer capability and targeting suitability of this cell line were 
tested by Dr. Annegret Wünsch, Dr. Mayuko Kurome and Katrin Krähe. 
All experiments were carried out under sterile conditions at a sterile bench. Media and 
solutions were pre-warmed to 37 °C and culture dishes were used at room 
temperature. Culture dishes were coated with CollagenR (0.2 mg/ml), diluted with 
aqua bidest. Cells were incubated at 37 °C, 5% CO2  and 95% humidity. 
3.2.1 Cell culture, passaging and cryopreservation 
Frozen Niere m cells (passage 1 or 2), stored in liquid nitrogen, were thawed by 
transferring the cells into 10 ml stop medium. After centrifugation at 180 × g for 
5 min the supernatant was discarded. The remaining cell pellet was resuspended in an 
appropriate amount of culture medium containing 10% FCS and transferred onto 
10 cm culture dishes (approximately 1 × 106 cells per dish). When the cells reached 
90% confluence they were passaged as follows. They were washed twice with PBS 
(equal amount as culture medium) and detached from the culture dish surface by 
incubation with 1.5 ml Trypsin/EDTA 0.5% for approximately 3 min until the cells 
got a round shape and became detached. The reaction was stopped with 10 ml stop 
medium and cells were transferred into an appropriate Falcon tube. A Neubauer 
Hemocytometer was filled with the stop medium containing the cells and the amount 
of cells was calculated. The appropriate volume containing 1 × 106 cells was 
transferred to a new reaction falcon and centrifuged at 180 × g for 5 min. The 
supernatant was removed and the cell pellet was resuspended with 10 ml culture 
medium containing 10% FCS and transferred to a 10 cm culture dish. For each 
transfection experiment two 10 cm culture dishes were prepared with 1 × 106 cells. 
The remaining cells were frozen in 1 ml pre-cooled FCS containing 10% DMSO, 
placed at -80 °C and later on transferred for storage in liquid nitrogen.  
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3.2.2 Transfection 
For the transfection of the cells the Amaxa Nucleofector™ Technology from Lonza 
was applied. This technology combines electrical pulses and cell type specific 
solutions in order to transfer the foreign DNA directly into the nucleus (HAMM et al., 
2002). Nucleofection solution, cuvette and plastic pipette were components of the 
AmaxaTM Basic NucleofectorTM Kit for Primary Mammalian Fibroblasts, Lonza.  
Cells were grown to a confluence of 60 – 80%, harvested and counted as described 
above (3.2.1). 5 × 105 or 1 × 106 cells were resuspended in 100 µl nucleofector 
solution, 5 µg of the modified targeting vector DNA was added and the reaction mix 
was transferred into a nucleofection cuvette and pulsed with the preset program U12. 
After nucleofection the cells were transferred with a plastic pipette into a 6-well 
culture dish in 3 ml culture medium containing 15% FCS . After 24 h the cells were 
evaluated culture medium was exchanged and 48 h after nucleofection the selection 
was started, except for nucleofection experiment 100831, in which selection was 
started after 24 h. Figure  III.1 gives a schematic overview of the nucleofection 
experiments.  
3.2.3 Selection 
It was necessary to produce cell clones originating from a single cell in order to screen 
for the correct genetic modification. The targeting construct carries a neomycin 
resistance cassette. Therefore, the selection medium contained 1.2 mg/ml geneticin 
(G418), which has been determined by Dr. Annegret Wünsch to be the optimal 
concentration for the Niere m cell line to eliminate cells without integrated construct 
within one week. Transfected cells as well as untreated Niere m cells were harvested 
and counted as described above (see 3.2.1). For optimal growth 2000 cells were 
seeded out into one 96-well. Thereby transfected cells were co-seeded with untreated 
cells in the ratios 1:4, 1:3 or 1:1. Medium was exchanged every 48 h and after 7 days 
the 96-well plates were screened for G418 resistant clones. Only wells containing 
single colonies were considered for further processing. When the cell clones reached a 
confluence of 70% they were washed twice with 200 µl PBS, treated with 30 µl 
trypsin/EDTA 0.5% for 3 min and resuspended with 170 µl selection culture medium. 
In the initial experiments where the targeting efficiency by homologous recombination 
was determined, each cell clone was just transferred into a new well of a 96-well plate 
to promote proliferation. In subsequent experiments the cell clones were splitted into 
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two wells (96-well plate), since one well was needed for screening and the other had 
to be cryopreserved, for potential SCNT (Figure  III.1). For screening the cell clones 
were trypsinized as soon as they reached 100% confluence, resuspended with 100 µl 
stop medium and centrifuged at 330 × g for 10 min. The supernatant was removed, the 
cell pellets were placed on crushed ice and then transferred to −80 °C for storage until 
DNA was isolated via high salt precipitation (see 3.1.7.1). The cells for potential 
SCNT were trypsinized when they reached a confluence of 80%. The reaction was 
stopped using directly 200 µl cryo medium. The cell solution was transferred to 1.5 ml 
reaction tubes, placed on ice and transferred within 30 min to −80 °C for storage. 
 
Figure  III.1 Schematic overview of the nucleofection experiments 
The linearized modified BAC vector, carrying a resistance cassette in exchange for the exon 
52 of the DMD gene was transfected into Niere m cells; cells with integrated vector were 
selected with G418, harvested, screening for correctly targeted cell clones and a backup 
portion was stored on – 80 °C for subsequent SCNT and ET. 
 
3.3 Nuclear transfer and embryo transfer 
Frozen portions of cell clones that were found to have undergone homologous 
recombination, were thawed by adding 1 ml stop medium and subsequent 
centrifugation for 5 min at 180 × g. The supernatant was discarded, the cell pellet 
resuspended in 300 µl culture medium with 20% FCS and splitted on three wells on a 
96-well culture plate. 48 h prior to SCNT cells were treated with starvation medium. 
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SCNT was carried out by Dr. Mayuko Kurome, Dr. Barbara Kessler, Dr. Valeri 
Zakhartchenko and Tuna Gungör according to the protocol described by KUROME et 
al., (2006). The obtained embryos were transferred to estrus synchronized gilts (ET) 
(BESENFELDER et al., 1997). After 3 weeks gilts were controlled by ultrasonic 
examination for the first time for conception and afterwards in regular intervals for 
preservation of the pregnancy.  
3.4 Characterization of the DMD pigs  
3.4.1 Quantitative stereological and morphometric analysis 
Determination of the muscle fiber proportion to the whole muscle volume of the 
musculus biceps femoris and the muscle fiber diameter (minimal Feret’s diameter) 
was conducted with twelve digital images (image size: 340 x 268 µm) of anti-
dysferlin immunostained cross sections of the musculus biceps femoris of three 
newborn DMD knockout piglets and three age matched controls. Images were taken 
with a Zeiss Axiovert 200 M fluorescence microscope (40x objective). 
The muscle fiber proportion to the whole muscle volume or the volume density of 
muscle fibers (VV(MF/M)) was determined by point counting in a randomly positioned 
rectangular test field with 40 evenly distributed points per test field (area of test field: 
57.8 × 103 µm2). The test field was superimposed over the images to be counted (12 
images per animal). The (VV(MF/M)) was calculated as the quotient of the cross section 
profile area of muscle fibers (points hitting muscle fibers) and the corresponding area 
of  muscle sections (points counted per animal; 12 × 40). 
For quantification of the muscle fiber size the minimal Feret’s diameter (minimum 
distance of parallel tangents at opposing particle borders) was determined (BRIGUET 
et al., 2004). A randomly positioned unbiased counting frame (GUNDERSEN, 1977) 
(counting frame area: 10.4 × 103 µm2) was superimposed over each of the twelve 
images per animal and the muscle fiber cross section profile were measured using a 
Videoplan image analysis system (Zeiss-Kontron, Munich).  
3.4.2 Gait and movement analysis 
Evaluation of gait and movement were carried out in comparison with weight matched 
controls. The DMD knockout pig was conditioned to follow persons offering it sweets 
as incentive. The control animals were trained to get accustomed to handling by daily 
apple feeding and playing. 
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For gait analysis a 15 meters long and 80 cm wide run was staked off with a fence 
along a wall. The ground was covered with grass. The DMD knockout pig followed a 
person through the run and the control animals were chased through with differing 
speed. The animals were filmed for comparison.  
Furthermore, the ability to climb a 25 cm step was tested. Therefore, the DMD pig 
was compared with a control animal.  
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IV. RESULTS 
1 DMD gene constitutive targeting vector  
For the establishment of a porcine DMD model with a loss of function of the protein 
dystrophin it was decided to delete exon 52 of the DMD gene, leading to a frame shift 
of the transcript. BAC vectors were chosen as targeting vector as it is assumed that an 
increased length of the homologous sequence leads to a higher targeting efficiency.  
For a constitutive knockout the DMD exon 52 and its flanking intronic regions were 
replaced by a neomycin/kanamycin (neokan) resistance cassette flanked by Cre 
recombinase recognition sites (loxP) as depicted in Figure  IV.1. The targeting 
construct replaced approximately 5.2 kb (134150 – 139440) of wild-type sequence 
including the exon 52 with the neokan resistance cassette. 
 
Figure  IV.1 Targeting by homologous recombination of exon 52 of the DMD 
gene in Niere m cells 
For the targeting of exon 52 of the DMD gene a BAC vector, carrying exon 52 and adjacent 
sequences, was modified by replacing the exon 52 with a neokan resistance cassette flanked 
by loxP sites (blue triangles). The resistance cassette was introduced into the BAC vector by 
recombineering between the two homologous arms 5’ and 3’. The modified BAC vector was 
used for targeting of the desired locus in Niere m cells by homologous recombination. 
 
1.1 Allelic differences of BAC vectors 
Amongst others BACs CH242-9G11 and CH242-27G20 were found to cover the 
genomic region comprising the exon 52 of the DMD gene. Their sequences were 
deposited in a pre-annotated status at the ensemble.org database. Alignment in 
BioEdit software of the sequences of BACs CH242-9G11 and CH242-27G20 showed 
an overlap of 27 kb. Besides several single nucleotide polymorphisms (SNP), two 
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major differences were found. An 8450 bp insert was found approximately 6660 bp 
upstream of exon 52 on CH242-9G11, but was missing in CH242-27G20. BLAST 
search of this insert identified it to be a L1 Transposon. Additionally a microsatellite 
was found 5540 bp upstream of exon 52 with differing length between the two BACs. 
As both BACs were obtained from a single Duroc female 
(http://www.ensemble.org/Sus_scrofa/Info/Index) the comparison of the sequences in 
the overlapping region indicates that the diversity of the pig population is high, even 
in so-called “defined” breeds. Although BAC vectors show long homologous regions 
that avoid decreased recombination efficiency due to SNPs, larger differences might 
influence the recombination process. Therefore, the genomic region around exon 52 
on the single X-chromosome of the Niere m cell line and on the genomic DNA from 
other individuals of different pig breeds was examined for both, the transposon 
integration and the microsatellite.  
The allelic character concerning the L1 Transposon of the Niere m cell line as well as 
several different pig breeds was examined by a screening PCR with common reverse 
primers and forward primers, specific for the integrated as well as for the non-
integrated transposon (Figure  IV.2).  
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Figure  IV.2 Screening PCR for L1 Transposon of genomic DNA of Niere m 
cells and several different pig breeds 
(A) Position of the L1 Transposon and microsatellite on the BAC sequences with primers for 
the screening the L1 Transposon are indicated as arrows; (B) Screening PCR for L1 
Transposon; amplicons with differing length are generated; (A/B) abbreviations: MS: 
microsatellite; ex52: DMD exon 52; w/o: without. 
 
Screening for the transposon integration revealed that the male cell line Niere m 
contained the insert, contrary to the genomic DNA from a Duroc female animal, 
which lacked the insert on both alleles. The female animals of the German Landrace 
breed as well as German Large White breed showed a heterozygous genotype.  
The region containing the microsatellite was sequenced from Niere m and several 
other different pigs from different breeds for further comparison. The obtained 
sequences are shown in Figure  IV.3.  
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Figure  IV.3 Sequencing results of the region containing the microsatellite of 
Niere m and several other animals of different breeds 
(A) Sequencing results of the microsatellite of the Niere m cell line and various animals of 
different breeds; (B) Sequencing results aligned to sequences of CH242-9G11 and 
CH242-27G20; (A/B) Fragments containing the microsatellite were obtained by PCR with the 
primer pair DMD-int51-MSf1 and DMD-int51-MSr1, an annealing temperature of 58°C and 
1 min elongation time; sequencing was done with T7, M13 as well as DMD-in51-MSf1 and 
DMD-int51-MSr1 primers. 
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Sequencing results showed varying length of the microsatellites in the different 
animals analyzed. However, CH242-9G11 and Niere m have the same number of 
CA-repeats. 
Altogether the data indicate a broad diversity of the examined polymorphisms in the 
pig population. Niere m and CH242-9G11 show the same genotype for the L1 
Transposon as well as the microsatellite. As major genetic modifications may have an 
influence on the targeting efficiency, the BAC CH242-9G11 was chosen for the 
targeting experiments. The SNPs between CH242-9G11 and Niere m were not further 
examined. 
1.2 Construction of the DMD gene targeting vector 
1.2.1 Assembly of the plasmid based modification vector 
The usage of a modified BAC vector as a targeting vector requires assembling of 
plasmid based modification vector that is introduced into a BAC via recombination. 
The modification vector was assembled from the 5’-homologous arm, 3’-homologous 
arm and the floxed neokan resistance cassette in a pBSK vector as indicated in Figure  
IV.1.  
The 5’-homologous arm and 3’-homologous arm, were amplified from intronic 
sequences from BACs, carrying the porcine exon 52 sequence (CH242-9G11, 
-520G21, -27G20). PCR’s annealing temperature was 60 °C and elongation time 
1.30 min for both primer pairs. DMD5SPf and DMD5PNBr gave rise to the 
5’-homologous arm amplicon of 582 bp and DMD3BNf and DMD3PKr to the 
3’-homologous arm of 407 bp. The homologous arms were ligated into 
pGEM®-T-easy Vector and sequenced. The SacI/BamHI digested 5’-homologous arm 
and the BamHI/KpnI digested 3’-homologous arm were ligated simultaneously into a 
SacI/KpnI linearized pBSK vector and sequenced. 
The neokan resistance cassette with a murine 3-phosphoglycerate kinase promoter 
(mPGK), a T7 promoter, a bovine growth hormone (bGH) polyadenylation site (pA) 
and with two flanking lox-sites was obtained by restriction digest with NsiI and 
BamHI and cloned into the PstI/BamHI linearized pBSK vector containing both 
homologous arms and sequenced for verification. 
The sequence of the final construct corresponded to the sequence, assembled in silico. 
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However, several nucleotide variations could be identified in the homologous arms, 
which could not be found on either BAC sequence (CH242-9G11 or CH242-27G20). 
On the 5’-homologous arm an “a” was exchanged with a “g” at 134077 bp of the 
CH242-9G11 sequence. On the 3’-homologous arm a “t” was exchanged with a “c” 
twice, once at 134014 bp and at 134077 bp. The respective positions were identical in 
CH242-27G20 and CH242-9G11, indicating that the polymorphisms were caused by 
PCR amplification. 
1.2.2 BAC modification 
BAC CH242-9G11 was chosen for targeting experiments as it shows equal allelic 
characteristics in the major polymorphic sites described above as the cell line Niere m 
used in targeting experiments. In order to modify the BAC it was transferred into a 
recombineering capable SW106 E.coli strain. One colony was obtained from 
electroporation and screened for the uptake of CH242-9G11 via PCR with sequence 
specific primers, for the homologous arms and the exon 52 (Figure  IV.4).  
 
Figure  IV.4 Screening PCR for the integration of CH242-9G11 in SW106 
cells 
Screening PCR with CH242-9G11 sequence specific primer pairs DMD5SPf and DMD5PNr, 
DMD3BNf and DMD3PKr and DMDexSf and DMDexBr, an annealing temperature of 60 °C 
and elongation time of 1.30 min; M: Marker 
 
The modification vector was excised with the restriction enzymes PacI and PvuI, 
purified and electroporated into competent cells of the heat induced SW106 E.coli 
strain carrying the BAC CH242-9G11. After selection on kanamycin 163 colonies 
were obtained, 27 colonies were picked for overnight cultures and screened for the 
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correct modification of the BAC by PCR (Figure  IV.5 A). In 5 colonies the BAC has 
undergone homologous recombination and was correctly modified (Figure  IV.5 B). 
DNA from two positively screened bacterial clones was chosen for electroporation of 
the modified BAC into DH10B bacterial cells. 274 colonies were obtained and 24 
picked for overnight cultures. 8 of the 24 DH10B colonies were screened for the 
modified BAC by PCR, 7 out of 8 clones reflected the screening result of the BACs in 
the SW106 cells (Figure  IV.5 C).  
 
Figure  IV.5 Screening PCR for the integration of the modified BAC CH242-
9G11 in SW 106 and DH10B cells 
(A) Primer positioning of DMDsc1f and DMDwtsc1r/DMDkosc2r on the wild-type BAC and 
the modified BAC represented schematically; (B) Screening of colonies obtained after 
recombineering with both reverse primers in SW106 cells; (C) Screening of colonies obtained 
after electroporation of the modified BAC into DH10B cells, they were only screened with the 
KO primer pair (DMDsc1f and DMDkosc2r); (B/C) PCR was run with an annealing 
temperature of 57 °C and an elongation time of 1 min; M: Marker; KO: modified BAC 
integrated; WT: wild-type BAC  
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Furthermore, the integrity of the modified BAC was examined by restriction digest of 
BACs CH242-27G20, CH242-9G11 and the modified CH242-9G11 with PvuII and 
XbaI respectively. The restriction pattern of CH242-27G20 and CH242-9G11 is 
significantly different, as they do only share an overlap of 27 kb while at least 120 kb 
are unique for both clones. In contrast was the restriction pattern of the unmodified 
and the modified CH242-9G11 quite similar, as they do only differ in a length of 6 kb 
while they share a common sequence of 150 kb. In silico digest of the pre-annotated 
CH242-9G11 sequence and its modified counterpart predicted that a 10553 bp band in 
the XbaI digest of the unmodified BAC is lost due to the exchange of exon 52 by the 
resistance cassette and the introduction of a XbaI recognition site, which gives rise to 
the additional bands of 5932 bp and 1223 bp in the modified BAC. The restriction 
digest of the BACs confirmed this prediction (Figure  IV.6): as a restriction fragment 
of the vector backbone is visible at approximately 10500 bp as well, the comparison 
of the intensities of the bands with 10553 bp band suggested a ratio of 2:1 and 
indicated the loss of the 10553 bp band in the modified BAC. The identification of the 
fragments 5932 bp and 1223 bp was not possible because of the great number of 
further bands. In the PvuII digest the modification of the BAC was more distinct, as 
the overall pattern was identical and a single 10280 bp band in the unmodified BAC 
was clearly lost by the modification. The additional fragments of the modified BAC 
4073 bp, 967 bp and 844 bp were not to be identified within the other bands of the 
restriction digest. PCR screening and restriction pattern of the modified BAC indicates 
that (i) the BAC was modified correctly and (ii) the BAC did not undergo aberrations 
during the transfection into the SW106 and the subsequent recombineering procedure. 
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Figure  IV.6 Restriction digests of the BACs CH242-27G20, CH242-9G11 and 
modified CH242-9G11 with XbaI and PvuII 
Additional XbaI and PvuII recognition sites in the sequence of the modified CH242-9G11 
BAC lead to variations in the band patterns of the respective BACs after restriction digest. 
Apart from that the band patterns correspond to each other; M: Marker 
 
1.2.3 Targeting BAC preparation 
Based upon the evaluation of the modified BACs, clone #1/2 was chosen and DNA 
was isolated endotoxin free for nucleofection experiments. Additionally DNA of the 
targeting vector was also isolated with the non-endotoxin free protocol midi prep and 
further processed in equal manner.  
25 µg of CH242-9G11 with the targeting construct could be obtained from the first 
endotoxin free isolation (#1). After digest with SfiI linearized BAC with a 
concentration of 685 ng/µl were available for targeting experiments in cell culture. In 
a second endotoxin free isolation 40 µg DNA of the modified BAC were isolated and 
after restriction digest with SfiI linearized BAC with a concentration of 955 ng/µl was 
obtained (#2). Further 88 µg modified BAC were isolated in a non-endotoxin free 
manner and linearized vector with a concentration of 3698 ng/µl (Midi Prep/PCiA) 
was produced. 
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2 Targeting of the DMD gene in primary porcine kidney cells 
2.1 Cell culture 
Five nucleofection experiments were carried out with the modified and linearized 
BAC CH242-9G11 (Table IV.1). For experiments 100203 and 100413 the same DNA 
was used (endotoxin free #1), for experiments 100831A and 100912 DNA from a later 
preparation was used (endotoxin free #2). 100831B was carried out with DNA, which 
was isolated following the conventional midi prep protocol. Nucleofection was 
performed with Niere m cells either in passage 3 or 4. For each experiment 5.0 × 105 
cells were transfected with 5 µg DNA, except for experiment 100912 in which 
1.0 × 106 cells were transfected. Selection with G418 was started with differing 
amount of cells, ranging from 4.0 × 105 and 52.8 × 105. However, selection in 
experiments 100831A and B was started 24 h after nucleofection, which may have 
contributed to the low cell number in these experiments. Selection in experiment 
100912 was started with 2.7 × 106 cells of the total 3.5 × 106 cell for reasons of 
feasibility. The remaining cells were cryopreserved. Furthermore, was the ratio of the 
co-seeded untreated cells to the transfected cells changed from 4:1 to 3:1 and 1:1 in 
the experiment 100912. A variable number of single cell clones, 0.1 ‰ - 0.2 ‰ of 
seeded transfected cells, was obtained after selection in each experiment. Except for 
experiment 100831B where no single cell clone was obtained. Overall 637 clones 
were splitted after selection, with values ranging from 0 to 275 clones. In experiments 
100203 and 100413 an almost equal number of clones (162 and 156 respectively) 
were splitted. A total of 436 clones were harvested for DNA isolation and 322 
portions of clones were harvested in passage 6 or 7 for cryopreservation, as the first 
experiment (100203) was carried out without generation of backup clones. Between 
the single experiments varying proportions from 22.7% to 42.9% of clones were lost 
after splitting.  
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Table IV.1 Transfection experiments of Niere m cells 
Nucleo-
fection  
Passage 
at 
nucleo-
fection 
Typ of 
DNA 
DNA 
volume  
5 µg (µl) 
Cells at 
selection 
start 
(×105) 
Single cell 
clones after 
selection 
Cell clones 
harvested / 
(%) 
100203 P3 EF #1 7.3 8.6  162 114 (70.4) 
100413 P3 EF #1 7.2 8.6  156 89 (57.1) 
100831 A * P4 EF #2 5.2 4  44 34 (77.3) 
100831 B * P4 PCiA 1.4 4.4 0 0 
100912 # P4 EF #2 5.2 27.2  275 199 (72.4) 
Total 
   
52.8 637 436 (68.4) 
EF: endo free 
* Start of selection 24 h after nucleofection 
# 1 × 106 cells transfected and seeded in the ratios of transfected to untreated cells of 1:1 and 
1:3  
 
2.2 Screening 
DNA was isolated via high salt precipitation from the 436 cell clones obtained in 
targeting experiments and used for screening of correct integration of the targeting 
construct by qPCR with the “loss-of-native-allele” assay. In correctly targeted cells 
the modified BAC integrates into the genome of the Niere m cells at the desired locus 
by homologous recombination and thereby the exon 52 of the DMD gene is replaced 
by the resistance cassette. Therefore, a primer pair (qPCRDMD11fw and 
qPCRDMD12rv) was designed on the targeting site specific wild-type DMD 
sequence. The primer pairs GGTA3423fw/GGTA3640rev and 
HPRT834i2fw/HPRT987i2rev on the sequence of the alpha(1,3)galactosyl transferase 
(GGTA) gene and the hypoxanthine phosphoribosyltransferase 1 (HPRT) gene 
respectively were established as reference amplicons by Katrin Krähe and Katrine 
Skou. In order to screen for correctly targeted cell clones the copy number of the 
amplicon of the DMD gene is compared to the copy number of the two reference 
genes. In the case of random integration of the targeting vector the DMD gene stays 
intact and leads to a copy number ratio of 1:1 (DMD/HPRT) or 1:2 (DMD/GGTA). In 
case of a successful targeting by homologous recombination no DMD amplicon can 
be detected and the ratios change to 0:1 and 0:2 respectively (Figure  IV.7).  
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Figure  IV.7 Schematic depiction of the qPCR screening method 
For the screening of correctly targeted clones the copy number of the target sequence was 
compared to the copy number of two reference genes. HPRT is located on the X-chromosome, 
whereas GGTA lies on an autosomal chromosome; mX: maternal X-chromosome; pY paternal 
Y-chromosome; WT: wild-type; pX paternal X-chomosome; mAut: maternal autosomal 
chromosome; pAut: paternal autosomal chromosome. 
 
The 436 samples were pooled into sets for the qPCR screening. Each set comprising 
up to 38 samples. From each set the copy numbers of the amplicons of the DMD, 
GGTA and HPRT primers were determined on individual plates, using the same 
standard curve with the same copy number values. Three calibrators on each plate 
were used for the calibration of the obtained copy numbers from the primer pairs for 
each sample. A cell clone with a calibrated copy numbers below 100 in any of the four 
values of the reference genes (GGTA and HPRT) was omitted from the set and was 
not considered in further processing. From the remaining samples the copy number 
ratio between the calibrated copy numbers of each primer pair were calculated: 
DMD/GGTA, DMD/HPRT and GGTA/HPRT. The mean value and standard deviation 
was calculated from the resulting four values for each primer pair ratio. Samples were 
excluded from the set when the standard deviation of any ratio was higher than 0.3. 
From all samples meeting the quality criteria (calibrated copy number >100, standard 
deviation of all ratios <0.3), those were considered positively targeted, which had a 
ratio of DMD to GGTA and DMD to HPRT below 0.1 and a ratio of GGTA to HPRT 
of 1 (see Table IV.2 and Table IV.3).  
In order to evaluate the reliability of the screening for correctly targeted cell clones by 
the comparison of the copy number ratios, characteristic values like the median, mean 
value, maximal value, minimal value and the standard deviation, were determined (see 
Table IV.2 and Table IV.3). Values of the correctly targeted clones for the 
DMD/GGTA and DMD/HPRT ratios are obviously outliers compared to the values of 
the remaining cell clones. The maximal value of the correctly targeted cell clone is 
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still 65 times smaller than the lowest value of the other cell clones. Moreover does the 
comparison of the median and mean value show that the ratios of the DMD copy 
number to the reference gene copy number is actually 0:1 in correctly targeted cell 
clones and 1:1 in negative cell clones. 
 
Table IV.2 Characteristic values of the mean values of the respective ratios 
of evaluated cell clones; correctly targeted cell clones are 
excluded 
 
DMD/GGTA DMD/HPRT GGTA/HPRT Total 
Median  1,097564 1,096151 0,942765 1,076487 
Mean value 1,121972 1,096243 0,979425 1,079678 
Maximal value 1,808750 1,416499 1,567319 1,808750 
Minimal value 0,633267 0,544155 0,635529 0,544155 
Standard deviation 0,164448 0,150268 0,187355 0,177088 
 
Table IV.3 Characteristic values of the mean values of the respective ratios 
of correctly targeted cell clones 
 
DMD/GGTA DMD/HPRT GGTA/HPRT 
Median  0,000698 0,000788 1,075482 
Mean value 0,002344 0,002411 1,044429 
Maximal value 0,007728 0,008360 1,241085 
Minimal value 0,000069 0,000061 0,832771 
Standard deviation 0,002891 0,003027 0,135488 
 
 
436 clones were screened by qPCR and the obtained data were analyzed. The set of 
samples #1-7 and #12 were examined for the copy numbers of DMD, GGTA and 
HPRT. The set of samples #8-11, #13 and #14 were examined only for DMD and 
GGTA. Cell clones from the latter set of samples that revealed a ratio of DMD/GGTA 
below 0.1 were verified within an extra set of samples (#12) using DMD, GGTA and 
HPRT primers. Of the 436 clones tested 381 met the quality criteria whereas 33 clones 
had a standard deviation higher than 0.3, 20 had a copy number below 100 and 2 
clones were not considered because of a pipetting error or backup contamination. 
Thus a total of 55 clones were excluded from the analysis.  
8 clones of the 381 evaluated clones had a ratio of DMD copy number to both 
reference gene copy numbers below 0.1 and were therefore considered as positively 
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targeted. All of the clones were analyzed in an independent set of samples, where they 
were confirmed as correctly targeted. A targeting efficiency of 2.1% of the DMD 
locus was achieved. The obtained ratios of qPCR plates with correctly targeted clones 
are illustrated in diagrams of Figure  IV.8 and Figure  IV.9. For a clearer illustration 
the ratio of GGTA to HPRT was left out. 
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Figure  IV.8 Set of samples #1 and #2 of the qPCR screening for correctly 
targeted cell clones  
Diagrams of the mean values of the ratios DMD/GGTA and DMD/HPRT of the set of 
samples #1 and #2 with the correctly targeted cell clones #1, #3, #13, #45 and #46; contrary to 
the cell clones with random integration events the ratio of the DMD copy numbers to the 
reference genes of cell clones, which have undergone homologous recombination tends to 
zero; actual ratios of correctly targeted clones are specified. 
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Figure  IV.9 Set of samples #6 and #12 of the qPCR screening for correctly 
targeted cell clones 
Set of samples #6 and #12 include the cell clones #168, #239 and #290, which have 
undergone homologous recombination; their copy number ratios of DMD/GGTA and 
DMD/HPRT tend to zero (white box), compared to the ratios of the other cell clones.  
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3 Generation and characterization of the DMD pig model 
3.1 Nuclear transfer and embryo transfer  
Cell clones #1, #3, #13, #45, #46, #168, #239 and #290 were considered as correctly 
targeted. From these cell clones #168, #239 and #290 were used for SCNT.  
Overall ten SCNTs and ETs with 1085 embryos were carried out by Dr. Barbara 
Kessler and Dr. Mayuko Kurome to date. Table IV.4 gives an overview of all 
conducted experiments. Two SCNT were performed using cell clone #239, five with 
#168 and three with #290. From the SCNTs five pregnancies originated, of which 
three pregnancies, each based upon a different cell clone, were delivered to term. One 
pregnancy was lost in the second half of the gestation period, whereas the second one 
was already lost in the first half.  
The pregnancy based upon cell clone #168 gave rise to two piglets (#1300 and 
#1301). Four piglets were born based upon cell clones #239 (#1249-1252) and #290 
(#1261-1264) respectively. 
  
Table IV.4 SCNTs and ETs with DMD knockout cell clones  
Cells 
clone  
Nucleo-
fection 
experiment 
NT-
Embryos US1 US2 US3  US4  
Piglets 
(n) 
 #168 100413 123 + (d 33) + (d 58) - (d 93)   
 #168 100413 116 + (d 32) - (d 57) - (d 92)   
 #168 100413 50 ? (d 25) - (d 33) - (d 62)   
 #168 100413 99 - (d 27) - (d 58)    
 #168 100413 120 + (d 29) + (d 55)   2 
 #239 100912 140 + (d 40) + (d 54) + (d 82) + (d 99) 4 
 #239 100912 61 - (d 25)     
 #290 100912 167 - (d 22) ? (d 40) - (d 82)   
 #290 100912 102 ? (d 23) - (d 34)    
 #290 100912 107 - (d 22) + (d 33) + (d 83)  4 
US 1-4: ultrasonic pregnancy controls; d: days after ET; +/-/?: pregnant/not pregnant/not to be 
determined  
 
3.2 Characterization of the DMD pig model 
Delivered DMD knockout piglets were genotypically and phenotypically analyzed. 
Muscle tissue samples were taken by Prof. Dr. Maggi Walter and Dr. Barbara Kessler 
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from the muscles m. biceps femoris, m. triceps brachii, longissimus dorsi, diaphragm 
and heart muscles of dead DMD piglets and aged matched controls. Additionally the 
kidneys were obtained for the establishment of primary cell lines. From all DMD 
knockout piglets ear tissue samples were taken for cell isolation. Blood samples were 
taken from the DMD knockout piglets #1249, #1251, #1263, #1264 and 5 age matched 
controls and values of the serum creatine kinase (CK) were determined by the Pig 
Clinic LMU, Munich. 
Besides the evaluation of genetic modification of the genome of the cloned piglets by 
PCR, they were also examined by immunoblot, histological and 
immunohistochemistry analysis by Prof. Dr. Maggie Walter and Dr. Benedikt Schoser 
from the Friedrich Baur Institut, Munich. Dead piglets were sent to the Institute for 
Veterinary Pathology of the LMU, Munich, for pathological examination by Dr. 
Andreas Blutke, Dr. Nadja Herbach, Dr. Daniela Emrich and Prof. Dr. Rüdiger 
Wanke. Andrea Klanner, Alexander Graf, Dr. Stefan Krebs and Dr. Helmut Blum, 
LAFUGA, Munich performed a whole transcriptome analysis. Cells were isolated and 
primary cell cultures established by Anne Richter. 
3.2.1 qPCR 
DNA for qPCR screening was isolated from kidney cells or ear fibroblasts 
respectively. qPCR was performed as described for cell clones from targeting 
experiments, yet two samples of each piglet were tested instead of one sample. The 
ratios of the copy number of the amplicons of exon 52 to the copy number of the 
reference genes tended to zero for all DMD knockout pigs (Figure  IV.10). DNA from 
already negatively tested cell clones was used as wild-type controls.  
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Figure  IV.10 Sets 1-3 of the qPCR screen of the delivered DMD knockout 
piglets 
DNA from delivered DMD knockout piglets was isolated and screened by qPCR for the loss 
of exon 52 of the DMD gene. Ratios of DMD/GGTA and DMD/HPRT are shown; DNA from 
formerly screened cell clones was used as wild-type controls. 
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3.2.2 End-point PCR 
Besides qPCR screening DNA from DMD knockout piglets was also screened by end-
point PCR for the loss of exon 52. Genomic DNA isolated from ear tissue samples via 
PCiA extraction protocol (#1249, #1250, #1251, #1252) and from ear fibroblasts via 
high salt precipitation (#1261, #1262, #1263, #1264, #1300, #1301) was used as 
template. No amplicons from the exon 52 could be detected in the DNA samples from 
DMD knockout pigs (Figure  IV.11).  
  
Figure  IV.11 Genotyping PCR of the delivered DMD knockout piglets 
(A) The primer pair designed on the sequence of the β-actin gene (PACT954f and 
PACT1919r) was used as reference for DNA integrity control; (B) Targeting site specific 
primers qPCRDMD5fw and qPCRDMD9rv were applied for the detection of exon 52 of the 
DMD gene; (A/B) Niere m DNA was used as wild-type control; Annealing temperature was 
60°C and elongation time 1 min.  
 
3.2.3 Transcriptome, immunoblot and histological analysis 
After the verification of the successful deletion of exon 52 on the genomic level, the 
transcribed RNA of two DMD knockout piglets of the first litter and of two wild-type 
controls was examined by RNA sequencing of the exon junctions between exons 50 to 
54 (Figure  IV.12). In the control animals, junctions between 50/51, 51/52, 52/53 and 
53/54 were readily detected, without any reads indicating alternative splicing. In the 
DMD piglets junctions between 50/51 and 53/54 could be detected, whereas no 
sequence of exon 52 was identified. However, transcripts with a junction between 
exons 51 and 53 were detected, that would lead to a + 1 frame shift resulting in six 
stop codons within exon 53 (two stop codons) and exon 54. Stop codons in exon 53 
are at least 100 nucleotides upstream of the exon junction between exons 53 and 54. 
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The number of reads detected also differs between the wild-type piglets and the DMD 
knockout piglets. Generally more reads are detected in wild-type controls. 
 
A Mutant
21 kb 133 kb
neoR
48 49 50 51 53 54 55
Wild type
  neoR
48 49 50 52 53 54 55
vector
2.4 kb 2.8 kb
d l d
52
51
  
e ete
B C
DMD532 bp -
w
t
01
w
t
02
w
t
03
#1
24
9
#1
25
0
#1
25
1
#1
25
2
#1
26
3
#1
26
4
H
2O
Wild type DMD mutant
DT T D
ED
ACTB
exon 52
970 bp -
 
Pig Human
420 kDa
D
M
W
T
W
T
D
M
 
Figure  IV.12 RNA sequencing of exon junctions in the transcript of the DMD 
gene 
Exon junctions 50/51, 51/52, 52/53 and 53/54 of two DMD knockout piglets and two wild-
type control animals were sequenced and the resulting stop codons depicted in the amino acid 
sequence (red crosses); lines between the exon boxes indicate the number of reads detected, 
the continuous line the reads from wild-type controls and the dotted line from DMD knockout 
piglets; kindly provided by Dr. Helmut Blum.  
 
Furthermore, the immunoblot analysis showed the loss of the protein dystrophin in the 
skeletal muscles of DMD knockout pigs #1249 and #1250 (Figure  IV.13); confirming 
the desired loss of function of the protein by the knockout of exon 52 of the DMD 
gene.  
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Figure  IV.13 Immunoblot of DMD knockout piglets #1249, #1250 and a 
wild-type pig compared to human samples 
The imunoblot demonstrates the loss of the protein dystrophin in the muscles of the DMD 
piglets compared to a wild-type control, mimicking the human situation. In order to show the 
equal loading of the gel the Coomassie-stained SDS gel is presented above; 20 µg protein 
were separated by 5.5% SDS-PAGE and blotted to a nitrocellulose membrane; dystrophin was 
labeled with monoclonal antibodies (NCL-DYS1 and NCL-DYS2, 1:150) and horseradish 
peroxidase-coupled polyclonal rabbit anti-mouse antibodies (PO260, 1:1000, Dako); 
antibodies were visualized using ECL reagent (RPN2106, GE Healthcare Amersham 
Bioscience); WT: wild-type; kindly provided by Prof. Dr. Maggie Walter. 
 
Immunostaining of muscle sections of DMD knockout piglets and wild-type controls 
was performed with two monoclonal antibodies against two different epitopes of the 
human dystrophin protein, the central rod domain and the COOH-terminal domain, 
with cross-reactivity to the porcine dystrophin protein. In order to illustrate the 
membrane integrity, a monoclonal antibody against a further membrane protein, 
dysferlin, was used. Staining of wild-type control exhibited a clear dystrophin signal, 
whereas almost no signal could be detected in samples of the DMD knockout pigs 
(Figure  IV.14). Providing a further evidence for the loss of a functional protein 
dystrophin. However, isolated revertant fibers could be found (not shown).  
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Figure  IV.14 Immunofluorescence analysis of DMD knockout pigs  
Samples are stained with primary antibodies against dystrophin (NCL-DYS1, NCL-DYS2, 
1:10, Novocastra) and against dysferlin (NCL-hamlet, 1:25, Novocastra) as membrane 
integrity control. Compared to the wild-type control no dystrophin is detectable in the muscle 
sections of the DMD knockout piglets. This finding corresponds to the situation in human 
DMD patients; secondary antibodies used were anti-mouse IgH (H+L) coupled to Alexa Fluor 
488 (1:300, A11029, Invitrogen-Molecular Probes) for dystrophin and biotinylated sheep anti-
mouse IgG (RPN 1001V, 1:100, GE Healthcare Amersham Bioscience) and Cy3 conjugated 
streptavidin (016-160084, 1:000, Dianova); WT: wild-type; kindly provided by Prof. Dr. 
Maggie Walter 
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The histological analysis of the muscles from the DMD knockout piglets by the 
Institute for Veterinary Pathology of the LMU Munich and the Friedrich Baur 
Institute, showed atrophic, hypertrophic and hypercontracted fibers, as well as muscle 
fibers with a rounded shape, basophilic staining, centrally located nuclei and differing 
fiber diameters (Figure  IV.15). Additionally focal interstitial fibrosis, mononuclear 
infiltration and focal calcifications were observed. 
 
 
Figure  IV.15 Histological examination of the muscles of 2 days old DMD 
knockout piglets 
Sections of the m. biceps femoris of the DMD knockout pig and a control wild-type animal 
were stained with hematoxylin and eosin; in the muscle of the DMD knockout pig centrally 
located nuclei (white arrows), rounded muscle fibers and a great variation of fiber diameters 
can be observed; original magnification: 400×; WT wild-type; kindly provided by Prof. Dr. 
Maggie Walter. 
 
The histology of the 3-months-old pig bore the same symptoms described for the 
younger piglets, but deteriorated (Figure  IV.16). Additionally branching fibers, 
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segmental necrosis of muscle cells with histiocytic cell infiltrations and a fatty 
replacement of muscle tissue could be observed. The heart muscle did not show any 
pathological changes, except for a few degenerating single fibers. 
These are signs of severe muscular dystrophy with muscle degeneration, regeneration 
and subsequent replacement of muscle tissue, also observed in human DMD patients.  
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Figure  IV.16 Histopathology of skeletal muscles of the three-months-old DMD 
pig 
A-D: Cross sections of the triceps brachii (A), biceps femoris (B), longissimus dorsi (C) and 
the diaphragm (D) demonstrating excessive variation of fiber diameters with hypertrophic 
rounded fibers. E (biceps femoris, cross section): Centrally located nuclei (arrows). F (triceps 
brachii, longitudinal section) and G (diaphragm, cross section):  Regenerating fibers 
(arrowheads). H (triceps brachii, longitudinal section; inset: biceps femoris, cross section): 
Branching/splitting of fibers. I (biceps femoris, longitudinal section) and J (diaphragm, cross 
section): Segmental necrosis of fibers (arrows in I, J, and in D) with peri- and endomysial 
mononuclear (histiocytic) cell infiltration. K (diaphragm, longitudinal section) and L 
(diaphragm, cross section): Interstitial fibrosis (blue color) and fatty replacement (asterisks in 
K) of muscle tissue. Paraffin sections. HE-staining (A-J), Trichrome-Masson-staining (K, L). 
Bars in A-D, F-L: 50 µm, bar in E: 10 µm; kindly provided by Dr. Andreas Blutke 
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Moreover the volume density of muscle fibres in the muscle (VV(MF/M)) was calculated 
and the muscle fiber Feret’s diameters were determined of three newborn DMD pigs 
and three age matched controls. 
For the VV(MF/M) an average of 354 ± 38 muscle fiber points were counted per case. 
The calculated volume density of muscle fibres in the muscle (musculus biceps 
femoris) of DMD piglets (0.71) and wild-type control animals (0.78) do not differ 
significantly (Figure  IV.17). 
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Figure  IV.17 Volume density of muscle fibres in the muscle of DMD piglets 
and wild-type controls 
VV(MF/M) of DMD piglets (n=3) and wild-type controls (n=3) was determined in the musculus 
biceps brachii; WT: wild-type, DMD: DMD knockout, VV: volume density. 
 
The minimal Feret’s diameter was measured in order to confirm the fiber diameter 
variations seen in muscle fiber cross sections. It was determined of an average of 
636 ± 74 muscle fiber cross sections per animal. The obtained data were categorized 
into ten diameter classes (≤ 4, 4.1-6, 6.1-8, 8.1-10, 10.1-12, 12.1-14, 14.1-16, 16.1-18, 
18.1-20 and ≥ 20.1), the data were divided into the respective classes and the 
proportion of the class on all measured diameters was calculated. To compare 
wild-type and DMD muscle phenotypes, p-values were calculated using an unpaired 
two-sample t-test, assuming equal variances. P-values of < 0.05 were considered 
statistically significant (Figure  IV.18). 
A left shift to smaller minimal Feret’s diameters of the muscle fiber cross sections of 
DMD piglets can be observed compared to the wild-type controls. 
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Figure  IV.18 Minimal Feret’s diameter of muscle fiber cross section profiles  
The minimal Feret’s diameter was determined of DMD knockout piglets (n=3) and age 
matched controls (n=3); obtained data was categorized into 10 classes; *: p < 0.05; WT: 
wild-type, DMD: DMD knockout 
 
3.2.4 Clinical analysis 
Serum CK levels from the examined DMD knockout piglets were grossly increased 
compared to age matched wild-type controls, serum CK levels being an indicator for 
pathological events of the musculature. Values of wild-type controls ranged from 
111-401 U/l with a mean value of 209 U/l. The values of the DMD piglets were 
generally increased: #1263 had 1649 U/l and #1264 2117 U/l. #1249 and #1251 had 
the highest values with 324324 U/l and 186984 U/l respectively.  
Piglets #1249 and #1251 from the first litter descending from clone #239 showed a 
severe phenotype congenitally. They had a highly impaired movement, not being able 
to move and feed on their own. When put to the sow’s teats they tried to suckle even 
lying on their side. They were euthanized shortly after birth. Piglets #1250 and #1252 
were able to move independently and feed on their own. They died within 24 h after 
birth, probably being crushed by their mother due to a decreased movement capability.  
Piglets #1261-1264, based upon cell clone #290, were delivered by cesarean because 
of a birth canal obstruction. #1261 and #1262 died during birth. #1261 displayed a 
macroglossia, which can be attributed to clonal side effects. The remaining two piglets 
were raised in an artificial feeding system (Figure  IV.19A). For the first few days 
their condition was impaired due to the anesthesia administered to the sow for the 
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cesarean. Afterwards they were able to move and feed on their own, however, their 
movement ability was impaired compared to age matched controls. After two weeks 
#1264 died due to diarrhea and pneumonia. #1263 was also affected by the disease, 
but survived after a treatment with spectinomycin. From birth onwards it showed 
growth retardation. Pig #1263 was measured twice a week from week six after birth to 
week eleven after birth (Table IV.5). Weighing was stopped in order to reduce the 
stress due to handling the DMD pig #1263 was exposed to, as an involvement of the 
heart muscle was assumed.  
Table IV.5 Weight comparison of wild-type pigs and DMD pig #1263 
weeks after 
birth 
Wild-type 
piglets (kg) 
#1263 at beginning/ 
end of the week (kg) 
6 10.0-12.8 -/7.4 
7 12.8-16.0 7.3/8.5 
8 16.0-19.5 9.5/10.5 
9 19.5-23.4 9.1/9.5 
10 23.4-27.6 11.9/12.6 
11 
 
11.9/- 
From: (KAMPHUS et al., 2004) 
 
The pig developed a progressive enlargement of the tongue and skeletal muscles, 
which was apparent from the age of approximately four weeks onwards (Figure  
IV.19B). With increasing age breathing, feeding and moving became progressively 
worse. #1263 died with the age of three months, because of an obstruction of the 
airways by the profound circumferential growth of the adjacent tissue. In the 
pathological examination the profound enlargement of the tongue and skeletal muscles 
and additionally of the laryngeal and pharyngeal muscles was confirmed. 
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Figure  IV.19 DMD knockout piglets #1263 and #1264 
(A) DMD knockout piglets #1263 and #1264 10 days after birth; kindly provided by Prof. Dr. 
Maggie Walter; (B) #1263 displaying a protruding tongue with the age of eight weeks. 
 
#1300 and #1301, descending from cell clone #168, were able to move and feed on 
their own after birth, although #1300 had a congenital malformation of the spinal 
column. #1300 died within 24 h hours after birth, death was probably caused by the 
congenital malformation. #1301 died within one week. Pathological examination 
showed enteritis and a persistent ductus arteriosus, which can be ascribed to the young 
age of the piglet.  
Locomotion analysis was performed with #1263 and two wild-type controls. As a 
consequence of the growth retardation, two weight matched piglets were used as wild-
type controls. At the time of the experiments, the DMD knockout pig was nine weeks 
old and weighted 12 kg. The control animals were four weeks old and weighted 11 kg. 
The wild-type controls showed a typical walking gait with a four-beat rhythm, setting 
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the claw of the hind leg almost exactly at the same place where the front claw has 
been set. #1263 showed an irregular rhythm and short strides particularly of the hind 
legs. Trotting the wild-type pigs showed a diagonal two-beat rhythm with wide 
strides. Compared to an irregular trot with short strides of the DMD knockout pig. 
Running the control pigs exhibited a typical fast four-beat gallop, whereas #1263 
showed a gallop with short strides, which had a hopping appearance of the hind legs. 
The overall movement seemed stiff and rigid compared to the wild-type controls. 
After several times passing the run the DMD piglet was fatigued and unwilling to 
carry on.  
Additionally the ability to climb a step was tested. The wild-type controls jumped onto 
the 25 cm step repeatedly, the DMD knockout pig was not able to climb the step once, 
as illustrated in Figure  IV.20.  
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Figure  IV.20 Comparison of the ability to climb a 25 cm  
The ability of the DMD knockout pig to climb a 25 cm step was compared to a weight 
matched wild-type control animal; the wild-type control jumped the step repeatedly, whereas 
the DMD knockout pig failed to climb the step even once; WT: wild-type. 
IV. Results   
 88 
In conclusion led the replacement of exon 52 of the DMD gene with an antibiotic 
resistance cassette by homologous recombination to a frame-shift of the transcribed 
RNA and subsequently to a loss of function of the protein dystrophin. The delivered 
piglets had a histological phenotype, which corresponds to the human situation and 
showed signs of muscular weakness combined with a progressive enlargement of the 
skeletal, pharyngeal, laryngeal and tongue muscles. 
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V. DISCUSSION 
DMD is a severe muscular wasting disease, resulting in the premature death of the 
affected persons (BLAKE et al., 2002). Beside management of symptoms and a 
treatment with glucocorticoids, which leads to a delay in the progression of the disease 
and a slight amelioration of the symptoms, there is no effective treatment available up 
to date (MANZUR et al., 2008). Animal models play a major role in the establishment 
of new treatments in clinical application (AIGNER et al., 2010), but as in the case of 
DMD, the existing animal models have different limitations in regard to the 
requirements set on an adequate animal model for DMD (WILLMANN et al., 2009). 
Pigs have been proven to be appropriate animal models for various applications in the 
field of biomedical research (AIGNER et al., 2010). Therefore, the aim of this work 
was to generate a tailored DMD pig model for advancement in therapeutical 
approaches and further investigation of the only partially understood 
pathomechanisms involved in the disease (DECONINCK & DAN, 2007). 
For the establishment of a DMD pig model, it was decided to delete exon 52. Several 
aspects were to be considered while designing an appropriate genetic modification, as 
it was necessary to cause a loss of function of the protein dystrophin, corresponding to 
the human situation (WILLMANN et al., 2009). DMD is caused by a great variety of 
mutations in the DMD gene, therefore a mutation with a high frequency in affected 
persons was chosen. 60 - 72% of the mutations are deletions of one or more exons 
(MUNTONI et al., 2003; AARTSMA-RUS et al., 2006), located in two mutational hot 
spots, a minor hot spot between exons 2 and 20 and a major hot spot spanning from 
exons 47 to 53 (KOENIG et al., 1987; DEN DUNNEN et al., 1989). Exon 52 is one of 
the more frequently deleted exons, leading to a frame shift of the transcribed RNA and 
thus to a loss of function of dystrophin. The aim of the intended application of the pig 
model in therapeutical research had to be considered as well, when selecting an 
appropriate mutation. Generally, the severe DMD phenotype is caused by the 
complete loss of dystrophin’s function, either due to a truncated non-functional 
protein or to a frame shift of the transcribed RNA, leading to a non-sense mediated 
decay of the RNA (KERR et al., 2001; MAQUAT, 2004). Whereas BMD patients 
have a mutation, which does not affect the reading frame and the produced dystrophin 
is shortened, but still more or less functional. One of the most promising therapeutical 
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approaches is the amelioration of the disease by transforming a DMD phenotype to a 
milder BMD phenotype through skipping a further exon (exon skipping) and thus 
restoring the reading frame (AARTSMA-RUS et al., 2009). It would therefore be 
advantageous if the DMD pig model would carry a mutation, which could be treated 
with exon skipping. Deletion of exon 52 would be treatable by skipping exon 51 and 
53, which constitutes a possible treatment for a variety of mutations and from which 
approximately 25% of human DMD patients would benefit. Furthermore, the 
treatment by skipping exon 51 is already in clinical stages and proof of concept has 
been demonstrated (VAN DEUTEKOM et al., 2007; KINALI et al., 2009; CIRAK et 
al., 2011; GOEMANS et al., 2011). However, the efficiency of exon skipping has to 
be optimized and questions, like the optimal timing of the respective treatment, the 
appropriate administration and dosage in dependence of the stage of the disease, still 
have to be solved (WOOD, 2010). Besides the three full-length isoforms, the 
knockout of exon 52 affects the shorter isoforms Dp260 and Dp140. Isoforms Dp116 
and Dp71 are still expressed, as their promoters are situated behind the deleted exon. 
Dp116 is expressed in the peripheral nervous tissue and Dp71 ubiquitously throughout 
the organism (BLAKE et al., 2002), except for the skeletal muscle (LEDERFEIN et 
al., 1992; AHN & KUNKEL, 1993). These isoforms however, lack the NH2 terminus, 
which is essential for the role of dystrophin at the muscular membrane and will 
therefore not affect the muscular phenotype (ERVASTI, 2007).  
The desired mutation of the DMD gene, the deletion of exon 52, required a defined 
site directed mutagenesis, which was to be introduced by homologous recombination 
using a bacterial artificial chromosome (BAC) as targeting vector. Alternatively to 
targeting by extended homologous arms, efficient strategies include the designer 
nucleases technologies and gene targeting by AAV vectors. The ZFN technology has 
already been successfully used in pigs to introduce targeted mutations (HAUSCHILD 
et al., 2011; WHYTE et al., 2011) and the combination of ZFN and homologous 
recombination, providing a further possibility for the introduction of a tailored 
mutation, has been successfully applied in human cells and in mouse cells (URNOV et 
al., 2005; CONNELLY et al., 2010). However, the design of appropriate ZNF pairs 
for the respective sequence and the off target effects of the ZFNs might still constitute 
possible drawbacks of this technology (PORTEUS & CARROLL, 2005). The recently 
established TALENs provide a further promising tool for targeted modifications of the 
genome (CHRISTIAN et al., 2010), as they are said to be easy to design and have a 
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high nuclease activity combined with a reduce cytotoxicity (MUSSOLINO et al., 
2011). AAV vectors have already been used for a successful targeting in the pig 
(ROGERS et al., 2008). Though the precise process is still unknown, the homologous 
recombination pathway of double strand repair is said to play a role (FATTAH et al., 
2008). The small packing size of 5 kb (HIRATA & RUSSELL, 2000; VASILEVA et 
al., 2006) and the special requirements on the lab in order to work with AAV vectors 
(Gentechnikgesetz and Gentechniksicherheitsverordung) made their use inappropriate 
for this study. 
The targeting by homologous recombination requires a targeting vector carrying the 
designed modification, in this case the deletion of exon 52 by replacement with a 
resistance cassette, as well as sequences upstream and downstream of the modification 
cassette, which are homologous to the target locus. It is said, that an increased length 
of homology leads to a higher targeting efficiency (DENG & CAPECCHI, 1992; 
SCHEERER & ADAIR). Therefore, BACs were considered as adequate targeting 
vectors, as they can contain genomic DNA fragments of up to 200 kb and even larger 
(SHIZUYA et al., 1992). BAC vectors have already been used for targeted 
mutagenesis in various mouse models (TESTA et al., 2003; VALENZUELA et al., 
2003; YANG & SEED, 2003) and human embryonic stem cells (SONG et al., 2010), 
achieving targeting efficiencies of up to 28%. Exon 52 of the porcine DMD gene was 
to be exchanged by homologous recombination with an antibiotic resistance cassette 
driven by a strong ubiquitously expressed promoter, in order to distinguish between 
cells with stably integrated transgene and negative cells. For the targeting, a 
neomycin/kanamycin resistance cassette, flanked by loxP sites, which was under the 
control of a mPGK and T7 promoter and had a bGH polyadenylation site, was used. 
The neomycin/kanamycin resistance cassette is frequently used for selection (VAN 
DER WEYDEN et al., 2002) and is well established in our lab as well as the 
ubiquitously expressed mPGK promoter (CHEAH & BEHRINGER, 2001). In the 
case of expression alterations caused by the selection cassette in or around the target 
locus, the resistance cassette flanking loxP sites provide the possibility to remove the 
disturbing fragment (FIERING et al., 1995; PHAM et al., 1996). The Cre recombinase 
is an efficient and reliable recombinase and also regularly used (SORRELL & KOLB, 
2005). The positive selection strategy however, doesn’t differentiate between random 
or site directed integration and a lot of clones have to be screened to find correctly 
targeted cell clone. Other selection strategies, like positive-negative selection (NAGY 
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et al., 2003) and gene trapping (SORRELL & KOLB, 2005), can be used to enrich 
correctly targeted cell clones. The frequently used positive-negative selection can 
generally achieve a 2-10 fold enrichment of correctly targeted cell clones. The overall 
efficiency of this method however, might be reduced due to damage of the negative 
selection cassette or the actual loss of it (SORRELL & KOLB, 2005). The application 
of this strategy in combination with BAC vectors is therefore unsuitable, as with an 
increasing length of the homologous arms the loss of the negative selection cassette 
becomes more likely. Equally, the quite efficient gene trapping approach by promoter 
trap (HANSON & SEDIVY, 1995) was considered unsuitable for the targeting of the 
DMD gene in primary kidney cells, as this method requires an active gene locus and it 
was not expected, that the DMD gene is generally expressed in kidney cells. Taking 
the expected high targeting efficiency, already achieved in other species’ cells, and the 
aspects mentioned above into consideration, it was decided to solely use the positive 
selection strategy for the targeting of the porcine DMD gene with a BAC vector.  
There are two different established phage based recombination protocols to introduce 
the desired modification into a BAC (ZHANG et al., 1998; COPELAND et al., 2001). 
BAC CH242-9G11 used for the targeting of the DMD gene was successfully modified 
by the protocol based on Copeland et al. 2001. The preassembled plasmid based 
modification vector, consisting of two homologous arms and the floxed resistance 
cassette, which was to be introduced by homologous recombination into the BAC 
vector, was examined by sequencing and several mutations, caused by PCR 
amplification, were found in the homologous arms. However, it seems that they did 
not inhibit the recombination process as 18.5% of the PCR screened colonies were 
correctly modified. During the recombination process in the SW106 cells unwanted 
rearrangements of the BAC vector might occur. Hence the modified BAC 
CH242-9G11 and the original CH242-9G11 were compared by restriction digest. 
Thereby the restriction pattern confirmed the integrity of the BACs, additionally 
expected minor changes of the restriction patterns proved the desired modifications of 
the BAC. These findings are in concordance with the statement, that BAC vectors are 
stable and convenient to handle (GIRALDO & MONTOLIU, 2001; LEE et al., 2001). 
Sequence comparison of the overlapping 27 kb of two of the available BACs 
containing exon 52 (CH242-9G11 and CH242-27G20) revealed several major allelic 
differences. Besides a number of SNPs, a L1 Transposon and a microsatellite were 
found in closer proximity of the exon 52. The BACs represent only the genomic 
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characteristic of one individual, since they were generated from one Duroc sow. 
Examinations of the genotype with regard to the two features of several other pigs 
from different breeds confirmed a great distribution of the L1 Transposon and also a 
high variance of CA-repeats of the microsatellite throughout the breeds. It was shown 
that a high isogenicity of the sequences involved in the recombination process is 
beneficial in mouse ESCs (TE RIELE et al., 1992), although it may not be essential in 
all cell types (SEDIVY et al., 1999). Even so it has been shown that the BAC vectors 
generally overcome the need for isogenicity (VALENZUELA et al., 2003) the two 
major allelic differences were considered to impede the recombination process. 
Therefore, the genotype of the cell line used for the targeting experiments (Niere m) 
was examined for the L1 Transposon and the length of its microsatellite. Due to the 
concordance of BAC CH242-9G11 and Niere m in the two major allelic differences, 
CH242-9G11 was chosen as targeting vector, although it may still differ from Niere m 
in some SNPs, which have not been examined further. However, the targeting 
efficiency of 2.1% achieved in this study with a BAC differing in several SNPs from 
the targeting sequence confirms the assumption that BAC vectors reduce the need of 
isogenicity. It also mirrors the high targeting efficiencies of BACs already achieved in 
previous studies (VALENZUELA et al., 2003; YANG & SEED, 2003). In contrast to 
generally low number of targeting events, especially in somatic cells 
(DOETSCHMAN et al., 1987; SEDIVY & SHARP, 1989; HASTY et al., 1991; 
SEDIVY & DUTRIAUX, 1999) BACs provide a convenient tool for the targeted 
introduction of a defined mutation into the genome of porcine primary kidney cells, 
without additional enrichment strategies. 
Five transfection experiments of the porcine primary kidney cell line Niere m with the 
linearized modified BAC vector were performed applying the nucleofection 
technology (HAMM et al., 2002), which is used routinely in our lab. All experiments 
were conducted with the same nucleofection program and the same nucleofection 
solution for primary mammalian fibroblasts. Reaction conditions however, varied in 
following parameters: cell confluence, DNA type, DNA volume, number of 
transfected cells, ratios of cells for co-seeding as well as time between nucleofection 
and selection start (see Table IV.1). A great variance of experimental conditions and a 
low number of experiments prohibited profound statistical analysis. However, the 
complete lack of any viable cell clone in experiment 100831B compared to the other 
four experiments may be ascribed to the DNA isolation method, as the endotoxins 
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were not removed from the DNA in this experiment. Overall 8 of 381 eventually 
evaluated cell clones were correctly targeted in the five nucleofection experiments: 
five cell clones in experiment 100203, two in experiment 100912 and one in 
experiment 100413. The diverging results obtained in these experiments for 
nucleofection can also be seen in several studies conducted to investigate the targeting 
efficiency and cell cytotoxicity by different transfection methods (JACOBSEN et al., 
2006; SKRZYSZOWSKA et al., 2008; CAO et al., 2010; MAURISSE et al., 2010; 
MO et al., 2010). Resulting cell clones were screened by the qPCR based “loss-of-
native-allele” assay (VALENZUELA et al., 2003; YANG & SEED, 2003), which 
provided a reliable tool to distinguish between clones undergone random integration 
of the targeting vector and correctly targeted cell clones. All copy number ratios of 
correctly targeted cell clones were far below the threshold set at 0.1 and the overall 
ratio values were quite stably at around 1 (see Table IV.2 and Table IV.3).  
Three correctly targeted cell clones were used in SCNT and ET. Overall ten SCNTs 
and ETs were conducted, resulting in five pregnancies. Two pregnancies were lost in 
the first and the second half of the gestation period respectively. The pregnancy rate 
(50%) and delivery rate (70%) lie in the range observed in our lab (Dr. Mayuko 
Kurome, personal communication). Mirroring the general observed nuclear transfer 
efficiency (CAMPBELL et al., 2005; VAJTA et al., 2007). Ten piglets were delivered 
from the remaining three pregnancies. In addition with the other litters obtained from 
nuclear transfer of the cell line Niere m, with site directed modifications introduced by 
BAC vectors (unpublished data from our lab), this confirms the suitability of this 
targeting strategy for SCNT.  
The knockout of exon 52 of the DMD gene in the delivered piglets was verified on the 
genomic level by the qPCR based “loss-of-native-allele” assay as well as by endpoint 
PCR. Furthermore, the transcriptome was analyzed for the resulting RNA transcripts. 
In wild-type controls all junctions between exons 50 to 54 respectively could be 
detected. In the DMD knockout piglets junctions between exons 50 and 51 as well as 
53 and 54 were detected, but no sequence of exon 52. However, transcripts with an 
exon junction between 51 and 53 were identified. The knockout of exon 52 therefore 
leads to a transcript with a +1 frame shift and thus resulting in several stop codons in 
exon 53 and 54 positioned to render the transcript target for nonsense mediated RNA 
decay (MAQUAT, 2004) as observed in human DMD patients (KERR et al., 2001). In 
immunoblot analysis and immunofluorescence staining of muscle fiber cross sections 
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no dystrophin was detectable with the antibodies against the rod domain and the 
COOH terminal, except for isolated revertant fibers, confirming the general loss of the 
functional product of the DMD locus at the muscle membrane. The antibody against 
the rod domain should detect any truncated dystrophin. As no truncated dystrophin is 
seen, the transcript may be target of nonsense mediated RNA decay. The shorter 
isoforms Dp166 and Dp71 are generally not expressed in the skeletal muscle and were 
not detectable (BLAKE et al., 2002; LEDERFEIN et al., 1992; AHN & KUNKEL, 
1993). 
The histological analysis of DMD knockout piglets showed the typical hallmarks of 
the human dystrophic muscle, like fibers with centrally located nuclei, a rounded 
shape, basophilic fibers and varying fiber diameters with a high proportion of fibers 
with a small diameter. Necrotic fibers, as well as fibrosis, fatty replacement and 
infiltrations of cells of the immune system were also identified (BELL & CONEN, 
1968; MCDOUALL et al., 1990; BLAKE et al., 2002). Additionally focal 
calcifications could be detected, which is also found in HFMD cats (GASCHEN & 
BURGUNDER, 2001). Initial measurements of the volume density of muscle fibers in 
the muscle of DMD knockout piglets compared to wild-type controls showed no 
significant difference. In combination with the increased proportion of smaller 
diameters of fiber cross sections determined by the measurement of the minimal 
Feret’s diameter may indicate an increased number of muscle fibers. However, further 
histological examinations have to be conducted in order draw any validated 
conclusions.  
Elevated serum CK values could be observed in all samples taken from DMD 
knockout piglets, compared to wild-type controls. Generally increased serum CK 
values are related with pathological processes of muscles in the pig (PLONAIT & 
BICKHARDT, 1988). They can also be mildly increased after exercise, yet the age 
matched control animals were treated and handled in the same way, thus suggesting a 
pathological origin. It has to be kept in mind, that the malign hyperthermia syndrome 
in the pig can cause elevated serum CK levels as well, but the piglets didn’t show any 
sign of this disease (SWINDLE, 2007). Therefore, the elevated serum CK levels seem 
to be caused by the pathological processes in the muscles of the DMD knockout 
piglets, comparable to the generally highly increased levels (5000-150000 U/l) of 
human DMD patients (VERMA et al., 2010). Piglets #1249 and #1251 had grossly 
elevated levels, even compared to piglets #1263 and #1264. The great differences 
V. Discussion    
 96 
between the individual piglets might correlate to the severe phenotype displayed by 
#1249 and #1251. For a profound analysis of the correlation of the serum CK levels 
and the phenotype, blood samples from DMD piglets as well as age matched wild-
type controls should be obtained at regular intervals. It should also be considered to 
determine the DMD pigs’ genotype concerning the malign hyperthermia syndrome, as 
one hypothesis for the pathophysiology of DMD is based on a disturbed calcium 
homeostasis by an increased influx through mechanosensitive voltage independent 
channels (DECONINCK & DAN, 2007) and the malign hyperthermia syndrome in 
pigs, caused by a mutation in the gene for the ryanodine receptor, is involved in 
calcium homeostasis in muscle cells as well (FUJII et al., 1991).  
All life born DMD piglets showed impaired movement ability from birth onwards 
with differing severity. Piglets #1249 and #1251 from the first litter were not able to 
move and feed on their own. Their siblings (#1250 and #1252), on the other hand, 
moved and fed independently, although they were probably both crushed by the sow 
due to a decreased speed of movements. Piglets #1263 and #1264 from the second 
litter were highly affected for the first few days by the anesthesia applied to the sow 
for the caesarean. Therefore, they could only be evaluated after a week’s time. They 
were then able to move and feed on their own, however, reduced movement ability, 
like an unsteady gait, was apparent. Piglet’s #1301 phenotype equaled #1250 and 
#1252 from the first litter. It was not possible to evaluate #1300 as it had a spinal 
malformation, which may cause gait disturbances and movement’s impairment. The 
malformation might be ascribed to the SCNT (PRATHER et al., 2004). Overall the 
DMD piglets showed a varying phenotype in young age. Only #1263 survived to an 
age of three months. Locomotion studies carried out with the nine-weeks-old DMD 
piglet showed an aberration of all gaits examined in comparison to weight matched 
controls. Characteristic for all gaits was a shortening of the strides and an irregularity 
of rhythm. The bunny hopping displayed by the DMD pig whilst galloping is also 
described in cats affected with HFMD (SHELTON & ENGVALL, 2005). In 
combination with the inability to climb a 25 cm step, the locomotion studies 
demonstrated a profound muscle weakness of the DMD knockout pig resembling the 
human situation (BLAKE et al., 2002), especially as the pig was not able to carry on 
after passing through the run several times. With increasing age #1263 showed an 
enlargement of all skeletal muscles. In order to distinguish between pseudo-
hypertrophy, hypertrophy or hyperplasia of the muscles further histo-pathological 
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examinations have to be carried out, including quantitative stereological and 
morphometric analysis. However, an increase of fatty and fibrous tissue was notable 
in initial histological examinations. It has to be kept in mind that the enlarged tongue 
might be due to clonal procedure, as piglet #1261 had also an enlarged tongue and 
macroglossia is frequently described in clonal offspring (PRATHER et al., 2004). It is 
known that human DMD patients can develop a pseudo-hypertrophy of various 
skeletal muscles (EMERY, 1993), even cases exist with macroglossia (WEISS et al., 
2007; MALHOTRA et al., 2011). Furthermore, is the phenotype of the cats affected 
with HFMD described with a characteristic enlargement of the muscles, particularly of 
the tongue muscles. The enlarged tongue has also been regularly seen in the GRMD 
dog (SHELTON & ENGVALL, 2005). Muscle hypertrophy is also apparent in the 
mdx mouse (DURBEEJ & CAMPBELL, 2002). However, as only one DMD pig 
reached the age of three months it is necessary to evaluate more pigs, in order to 
confirm these findings.  
Additionally in piglet #1263 growth retardation was observed. This might have been 
caused by several reasons. First of all the piglets of the second (#1261-1264) and third 
(#1300-1301) litter were raised with an artificial feeding system, after piglets #1250 
and #1252 of the first litter were presumably crushed by the sow. They were fed milk 
powder for piglets solved in warm water. It is unsure if the artificial feeding system 
represents an appropriate replacement for the sow as they completely lack the supply 
of stable specific maternal antibodies by the sow’s milk, although piglets were fed 
with colostrum after birth. Diarrhea was often observed in the DMD piglets, which 
may have been caused by the milk powder or by impaired immune mechanisms. 
However, we did not raise any piglets in our lab in this manner at that time, therefore 
there were no wild-type piglets the DMD piglets could be compared to. It has to be 
kept in mind that the DMD knockout piglets can have an impaired movement and be 
therefore more prone to be crushed by the sow. In order to minimize the losses of 
piglets due to diarrhea and other diseases or due to the sow, the rearing system has to 
be evaluated and optimized.  
The SCNT procedure has been described to give rise to epigenetic alterations 
involving changes in DNA methylation and histone modifications (ZHAO et al., 
2010), which in this case might lead to altered gene expression levels between the 
single cell clones as well as individual cells and thus cause the different phenotypes 
observed in the newborn DMD piglets. Expression levels of genes involved in the 
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regenerating capacity and the up regulation of utrophin, functionally replacing 
dystrophin, are said to be responsible for the mild phenotype in the mdx mice 
(DURBEEJ & CAMPBELL, 2002). Furthermore, phenotype variations in several 
human DMD patients are ascribed to a different expression of genes influencing the 
alternative splicing process, causing the expression of a truncated dystrophin in some 
muscle fibers (revertant fibers) by the restoration of the reading frame (MUNTONI et 
al., 2003). Isolated revertant fibers were identified in the immunohistochemistry of the 
skeletal muscle of DMD piglets. In the long term the production of DMD pigs is to be 
achieved by establishing a breeding line. Phenotype variations in the cloned offspring 
might not be apparent in piglets obtained by breeding. The persistence of differences 
in the phenotype would constitute a limitation to the application of the DMD pig in 
the establishment of new treatment strategies, as the variable phenotypes impair the 
comparability of the experiments (WILLMANN et al., 2009). They could however, be 
advantageous for the investigation of mechanisms involved in the disease 
pathogenesis and for studying compensatory processes. A thorough characterization of 
the muscle pathology caused by DMD in the pig and the comparison of expression 
profiles between the individual DMD pigs, might lead to the new insights and 
improvement of the current knowledge of the muscular dystrophy.  
The reduced life span however, caused by the obstruction of the airways by the 
enlarged muscles of tongue and larynx, observed in #1263, might constitute a 
hindrance for the generation of DMD pigs, as the production of DMD pigs from 
backup portions of correctly targeted cell clones is limited, and the recloning 
efficiency is reported to be very low (unpublished data from our lab). An increased 
life span to at least sexual maturity (> 6 months) would facilitate breeding of the 
DMD pigs, even if the muscle dystrophy would lead to infertility. The possibility of 
the collection of sperm for intratubal insemination provides an alternative method 
(VAZQUEZ et al., 2008). In the case that further DMD pigs also display a muscle 
enlargement and therefore do not reach sexual maturity, it can be taken under 
consideration to surgically remove the obstructions. Surgical procedures in the larynx 
are already established in the pig (MURISON et al., 2009). Furthermore, a female cell 
line could be used for targeting experiments to produce DMD sows for breeding, as 
females do very rarely display a severe DMD phenotype (EMERY, 1991). 
Treatment strategies like gene replacement and exon skipping can be examined with 
the DMD piglets devoid of exon 52 (GOYENVALLE et al., 2011; PICHAVANT et 
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al., 2011). Especially the treatment by skipping of exon 51, which has already been 
tested with positive results in clinic trials (VAN DEUTEKOM et al., 2007; KINALI et 
al., 2009; CIRAK et al., 2011; GOEMANS et al., 2011), can be improved further. 
Certain aspects like the overall distribution and exon skipping efficiency have to be 
optimized (WOOD, 2010). The DMD pig offers the possibility to assess the efficiency 
of a certain treatment, the (side-) effects it causes throughout the organism, also in 
respect of long-term treatment. It could be utilize to solve questions like the optimal 
timing of the respective treatment, the appropriate administration and dosage in 
dependence of the stage of the disease.  
Overall the DMD pigs display several aspects, which do comply with the 
requirements set for an ideal DMD animal model (WILLMANN et al., 2009). Their 
genetic modification is a mutation, frequently found in human DMD patients. It 
results in the complete loss of any functional protein dystrophin and thereby leads to a 
phenotype, which resembles the human situation. The establishment of a DMD 
breeding line and thorough characterization of the DMD knockout pigs, would render 
the porcine DMD animal model with the knockout of exon 52 an attractive possibility 
to evaluate, refine and advance therapeutical approaches for DMD treatment, as well 
as study pathological mechanisms 
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VI. SUMMARY 
Generation of a tailored pig model of Duchenne muscular dystrophy  
Duchenne muscular dystrophy (DMD), one of the most frequent heritable lethal 
muscular diseases, is characterized by a progressive muscle weakness leading to the 
premature death of affected persons. The disease is caused by a variety of mutations in 
the DMD gene, resulting in a loss of function of the protein dystrophin and 
subsequently in muscle degeneration. Up to date, no effective treatment is available, 
however, several promising therapeutical approaches are under investigation. Animal 
models are needed to develop, evaluate, refine and improve effective therapies for 
DMD. Existing animal models however, are of limited relevance. As the pig has 
proven to be an adequate animal model for various human diseases, it was decided to 
generate a tailored porcine DMD animal model.  
Aim of this thesis was the production of a porcine DMD animal model, by introducing 
a defined mutation into the porcine DMD gene, which leads to a loss of function of the 
protein dystrophin. In order to provide an animal model with a mutation, which 
represents a great proportion of human DMD patients and is also target of several 
treatment approaches, exon 52 was to be deleted. Exon 52 was replaced by 
homologous recombination with an antibiotic resistance cassette using a bacterial 
artificial chromosome (BAC) as targeting vector. The desired mutation was 
introduced into the BAC by recombineering. DNA from the linearized modified BAC 
was transfected into primary porcine kidney cells by nucleofection. Obtained single 
cell clones were screened by the qPCR based “loss-of-homozygozity” assay, resulting 
in a targeting efficiency of 2.1%. Correctly targeted cell clones were used for nuclear 
transfer and subsequent transfer of cloned embryos into recipient gilts. Ten nuclear 
transfers were carried out resulting in three pregnancies delivered to term, each 
pregnancy originating from a different cell clone. Altogether ten piglets were born. 
Two were still born; seven were euthanized or died within two weeks, and one DMD 
piglet survived until the age of three months. With increasing age it developed a 
progressive enlargement of the skeletal muscles, also the tongue muscles and, as 
shown in the pathological examination, of the pharyngeal as well as laryngeal 
muscles. The knockout of exon 52 of the DMD piglets was verified on the genomic 
and transcriptomic level. Immunoblot and immunohistochemistry analysis showed the 
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loss of the dystrophin protein in the skeletal muscle, confirming the desired loss of 
function. Histological analysis of the skeletal muscles of the DMD piglets showed 
similar signs of degeneration and regeneration, as can be observed in human DMD 
patients. Furthermore, the measured serum creatine kinase values of DMD piglets 
were grossly increased compared to age matched controls. Locomotion studies were 
performed with the nine-weeks-old DMD piglet and weight matched controls. 
Alteration of gait patterns, impairment of movement capability and a striking muscle 
weakness could be observed. These findings render the tailored DMD pig a promising 
model to gain new insights in the DMD research.  
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VII. ZUSAMMENFASSUNG 
Generierung eines Schweinemodells für die Duchenne Muskeldystrophie  
Die Duchenne Muskeldystrophie (DMD) ist eine der häufigsten muskulären, letal 
verlaufenden Erbkrankheiten. Der Krankheitsverlauf ist geprägt durch eine 
progressive Muskelschwäche, die schließlich zum Tode des Patienten führt. Die 
Krankheit wird durch verschiedene Mutationen im DMD Gen verursacht, die 
letztendlich zu einem Funktionsverlust des Proteins Dystrophin führen, und 
nachfolgend den Untergang von Muskelfasern bedingen. Bis zum heutigen Tag gibt es 
keine effektiven Behandlungen; es existieren jedoch einige vielversprechende 
Therapieansätze.  
Mittels der bereits existierenden Tiermodelle konnten Einblicke in die 
Pathophysiologie von DMD gewonnen werden, allerdings ist ihr Nutzen in der 
klinischen Forschung auf Grund von geno- bzw. phänotypischen Abweichungen zur 
Situation beim Menschen limitiert. Das Schwein hat sich in vielerlei Hinsicht als ein 
adäquates Tiermodell für eine Reihe von verschieden humanen Erkrankungen 
erwiesen.  
Deshalb war es Ziel dieser Arbeit, ein Schweinemodell zu entwickeln, das, ähnlich 
wie beim Menschen, einen Funktionsverlust des Proteins Dystrophins, verursacht 
durch eine definierte Mutation im DMD Gen, aufweist. Um das Schweinemodell mit 
einer Mutation auszustatten, die einen großen Anteil der humanen DMD Patienten 
repräsentiert und zusätzlich noch Ziel mehrerer Therapieansätze ist, wurde 
beschlossen, eine Deletion des Exons 52 einzuführen. Das Exon 52 sollte durch 
homologe Rekombination mit einem bakteriellen artifiziellen Chromosom (BAC) als 
Targetingvektor durch eine Antibiotikaresistenzkassette ausgetauscht werden. Die 
gewünschte Mutation wurde mittels „Recombineering“ in den BAC eingefügt. DNA 
des linearisierten, modifizierten BACs wurde mittels Nukleofektion in primäre 
porcine Nierenzellen transfiziert. Gewonnen Einzelzellklone wurden anhand des 
„Verlust-des-nativen-Allels“ Assays basierend auf einer qPCR überprüft; die 
ermittelte Targetingeffizienz betrug 2.1%. Positive, geeignete Zellklone wurden 
anschließend im Kerntransfer eingesetzt und die gewonnen Embryonen auf Sauen 
übertragen, woraus insgesamt drei Würfe mit zusammen zehn Ferkeln resultierten. 
Jeder Wurf basiert auf einem andern Zellklon. Zwei der zehn Ferkel waren 
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Totgeburten, sieben wurden euthanasiert oder starben innerhalb der ersten zwei 
Wochen. Nur ein Schwein überlebte bis zu einem Alter von drei Monaten. Mit 
zunehmendem Alter konnte man bei diesem Schwein Umfangsvermehrungen  der 
Skelettmuskulatur, der Zunge sowie der Pharynx-, als auch Larynxmuskulatur 
beobachten. Der Knockout des Exons 52 in den DMD Ferkeln wurde auf DNA- und 
RNA-Ebene durch verschiedene Methoden nachgewiesen. Im Immunoblot und in 
immunhistochemischen Untersuchungen konnte kein Dystrophin nachgewiesen 
werden. Die histologischen Untersuchungen von Skelettmuskeln der DMD Ferkel 
zeigten Symptome der Degeneration und Regenration, wie sie typischerweise im 
Muskel humaner DMD Patienten vorkommen. Klinisch konnten erhöhte Serum-
Kreatinkinase-Werte gemessen werden. Vergleichende Bewegungsanalysen ergaben 
Unterschiede in den einzelnen Gangarten, wie auch eine Verminderung der 
Bewegungsfähigkeit und eine gravierende Muskelschwäche. Diese Resultate machen 
das DMD Schwein zu einem vielversprechenden Tiermodell um neue Einblicke in die 
DMD Forschung zu gewinnen.  
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